Functional Consequences of Cantu Syndrome Associated Mutations in the ATP Sensitive Potassium Channel by Cooper, Paige
Washington University in St. Louis
Washington University Open Scholarship
Arts & Sciences Electronic Theses and Dissertations Arts & Sciences
Winter 12-15-2015
Functional Consequences of Cantu Syndrome
Associated Mutations in the ATP Sensitive
Potassium Channel
Paige Cooper
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted
for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For
more information, please contact digital@wumail.wustl.edu.
Recommended Citation
Cooper, Paige, "Functional Consequences of Cantu Syndrome Associated Mutations in the ATP Sensitive Potassium Channel"
(2015). Arts & Sciences Electronic Theses and Dissertations. 644.
https://openscholarship.wustl.edu/art_sci_etds/644
  
WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Molecular Cell Biology  
 
Dissertation Examination Committee:  
Colin G. Nichols, Chair  
Sarah K. England 
Chris J. Lingle 
Jeanne M. Nerbonne 
Maria S. Remedi 
 
 
 
Functional Consequences of Cantu Syndrome Associated Mutations in the ATP Sensitive 
Potassium Channel 
by 
Paige E. Cooper 
 
 
A dissertation presented to the  
Graduate School of Arts & Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
 
December 2015 
Saint Louis, Missouri
ii 
  
Table of Contents 
LIST OF FIGURES ....................................................................................................................... iii 
LIST OF TABLES .......................................................................................................................... v 
ACKNOWLEDGEMENTS ........................................................................................................... vi 
ABSTRACT OF THE DISSERTATION ..................................................................................... vii 
CHAPTER 1: INTRODUCTION ................................................................................................... 1 
1.1 KATP Channel Protein Topology ........................................................................................... 3 
1.2 KATP Channel Stoichiometry/Trafficking/Subunit Pairing ................................................... 5 
1.3 KATP Channel Activity Regulation ........................................................................................ 6 
1.4 KATP Channels in Tissue ..................................................................................................... 14 
1.5 KATP Channels in Pathophysiology ..................................................................................... 23 
CHAPTER 2: METHODS ............................................................................................................ 31 
CHAPTER 3: CANTU SYNDROME RESULTING FROM ACTIVATING MUTATION IN 
THE KCNJ8 GENE ...................................................................................................................... 34 
3.1 Introduction ......................................................................................................................... 34 
3.2 Methods ............................................................................................................................... 34 
3.3 Results ................................................................................................................................. 34 
3.3 Discussion ........................................................................................................................... 41 
CHAPTER 4: DISEASE CAUSING SLIDE HELIX RESIDUE MUTATION IN KIR6.1 AND 
KIR6.2 ........................................................................................................................................... 47 
4.1 Introduction ......................................................................................................................... 47 
4.2 Results ................................................................................................................................. 47 
4.3 Discussion ........................................................................................................................... 56 
CHAPTER 5: DIFFERENTIAL MECHANISMS OF CANTU SYNDROME-ASSOCIATED 
GAIN-OF-FUNCTION MUTATIONS IN THE ABCC9 (SUR2) SUBUNIT OF THE KATP 
CHANNEL ................................................................................................................................... 58 
5.1 Introduction ......................................................................................................................... 58 
5.2 Methods ............................................................................................................................... 58 
5.3 Results ................................................................................................................................. 59 
5.3 Discussion ........................................................................................................................... 72 
CHAPTER 6: DISCUSSION ........................................................................................................ 78 
REFERENCES ............................................................................................................................. 86 
iii 
  
LIST OF FIGURES 
Figure 1.1- The genes encoding KATP channel proteins.................................................................. 2 
Figure 1.2-Topology and stoichiometry of the KATP channel complex. ......................................... 4 
Figure 1.3-Nucleotide Binding and Regulation of the KATP channel .............................................. 8 
Figure 1.4- PKA and PKC signaling pathway regulation of the KATP channel ............................ 12 
Figure 1.5-The role of KATP channel activity in hypothalamic glucose-sensing neuron function 17 
Figure 1.6-Hypothesized role of KATP channels in SNr neuron function. .................................... 19 
Figure 1.7-The role of KATP channels in beta cell function .......................................................... 20 
Figure 1.8-The role of KATP channels in cardiomyocyte function ................................................ 21 
Figure 1.9-The role of KATP channels in smooth muscle cell function ......................................... 24 
Figure 1.10-The role of KATP channels with decreased activity in the function of beta cells in 
PHHI patients .............................................................................................................. 26 
Figure 1.11-The role of overactive KATP channels in the beta cell function of NDM patients..... 28 
Figure 3.1- Gain-of-function KCNJ8 mutation Kir6.1[Cys176Ser] underlies Cantu syndrome .. 36 
Figure 3.2-Increased channel activity in basal and stimulated conditions in intact cells expressing 
Kir6.1[C176S]-containing KATP channels .................................................................. 39 
Figure 3.3- Increased relative efflux in basal and stimulated conditions in intact cells expressing 
Kir6.1[C176S]-containing KATP channels .................................................................. 40 
Figure 3.4- Increased channel activity in basal and stimulated conditions in reconstituted 
heteromeric KATP channels containing Cys176Ser subunits. ...................................... 42 
Figure 3.5- Reduced ATP-sensitivity of reconstituted heteromeric KATP channels containing 
Kir6.1[Cys176Ser] subunits ........................................................................................ 43 
Figure 4.1-Homomeric Kir6.1-V65M–but not Kir6.1-V65L–expressed with SUR1 increases 
KATP channel activity under basal conditions and in the presence of diazoxide in intact 
cells. ............................................................................................................................ 49 
Figure 4.2- Homomeric Kir6.1-V65M (but not Kir6.1-V65L) expressed with SUR2A increases 
KATP channel activity under Metabolic Inhibition (MI) and in the presence of 
pinacidil in intact cells. ............................................................................................... 50 
Figure 4.3- Homomeric Kir6.2-V64M–but not Kir6.2-V64L– expressed with SUR1 increases 
KATP channel activity in basal conditions and in the presence of Diazoxide in intact 
cells ............................................................................................................................. 51 
iv 
  
Figure 4.4- Homomeric Kir6.2-V64M–but not Kir6.2-V64L–with SUR2A increases KATP 
channel activity in basal conditions and in the presence of pinacidil in intact cells. .. 52 
Figure 4.5- Gain of function in Kir6.2-V64M due to decreased ATP-sensitivity. ....................... 54 
Figure 4.6- Increased open state stability in Kir6.2-V64M-based channels underlies decreased 
ATP sensitivity............................................................................................................ 55 
Figure 5.1-Cantu Syndrome mutations in SUR2. ......................................................................... 60 
Figure 5.2- Increased channel activity in intact cells expressing homomeric P429L, A475V or 
C1039Y-containing KATP channels ............................................................................. 61 
Figure 5.3-KATP conductance is increased in basal and stimulated conditions in intact cells 
expressing homomeric P429L and A475V-based KATP channels ............................... 62 
Figure 5.4-Relative KATP conductance is markedly increased in basal and stimulated conditions 
in intact cells expressing homomeric C1039Y KATP channels ................................... 64 
Figure 5.5-ATP-sensitivity is decreased in C1039Y channels ..................................................... 66 
Figure 5.6- C1039Y channels decreased ATP-sensitivity is due to increased Po. ........................ 67 
Figure 5.7-P429L and A475V show enhanced MgADP activation .............................................. 68 
Figure 5.8- Channel activity in cells expressing heteromeric P429L, A475V or C1039Y-based 
KATP channels. ............................................................................................................. 70 
Figure 5.9- KATP conductance normalized in the basal condition and in stimulated conditions for 
heteromeric P429L, A475V or C1039Y-based KATP channels ................................... 71 
Figure 5.10- Decreased sensitivity to glibenclamide inhibition in C1039Y channels. ................. 73 
 
  
  
v 
  
LIST OF TABLES 
Table 1.1- Native KATP Channel Composition in Various Tissues ................................................. 7 
Table 6.1-Cantu Syndrome Mutations and Clinical Symptoms. .................................................. 82 
 
  
vi 
  
ACKNOWLEDGEMENTS 
First, I would like to acknowledge my committee members for their help and, more 
importantly, patience in this process. I am grateful, and definitely couldn’t have been successful 
without your guidance. Equally essential are the sources from which I have been funded during 
my PhD, which include both the DBBS-Cell and Molecular Biology Training Grant and 
Cardiovascular Training Grant. 
I must acknowledge the Nichols lab, both past and present, for the many questions 
answered, techniques taught, and all the fun times. Specifically, I want to thank Yu Wen, who 
pulled the short straw, but still patiently taught me everything I know about inside-out patch 
clamping and rubidium effluxes, both of which were critical techniques in this project. Monica, 
who collaborated with me and helped translate my first manuscript into actual scientific writing. 
Sun Joo and Jeff, my positive peer-pressure, from whom in attempting to replicate the energy 
effort they put in, I learned my dedication to getting experiments done. William Borschel, for 
teaching me all I know about PowerPoint animations, letting me use your cells when my 
planning was poor, and giving a heroic effort to help with editing my thesis introduction. 
I’d also like to acknowledge the best administrative ladies in all of Wash U: Paula 
Reynolds and Stacy Kiel for keeping me in line and just putting up with all of my random 
questions and requests. You both made sure I was functioning as a person so I could do the 
science, and for that I am thankful.  
Finally I’d like to acknowledge and thank Colin. From your guidance and rigorous 
standard of doing, presenting and writing science I have benefitted greatly. Thank you for taking 
me on as a student and providing a strong foundation on which I can continue to develop as a 
scientist. I am eternally grateful. 
vii 
  
ABSTRACT OF THE DISSERTATION 
Functional Consequences of Cantu Syndrome Associated Mutations in the ATP Sensitive 
Potassium Channel 
by 
Paige E. Cooper 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2015 
Professor Colin G. Nichols, Chair 
ATP-sensitive potassium (KATP) channels are composed of inward-rectifying potassium channel 
pore-forming subunits (Kir6.1 and Kir6.2, encoded by KCNJ8 and KCNJ11, respectively) and 
regulatory sulfonylurea receptor subunits (SUR1 and SUR2, encoded by ABCC8 and ABCC9, 
respectively). These channels couple metabolism to excitability in multiple tissues. Mutations in 
ABCC9 have been linked to Cantú syndrome (CS), a multi-organ disease characterized by 
congenital hypertrichosis, distinct facial features, osteochondrodysplasia, and cardiac defects. 
Additionally, two ABCC9 mutation-negative patients, exhibiting clinical hallmarks of CS, have 
been identified as having KCNJ8 mutations. This body of work is focused on determining the 
functional consequences and molecular mechanisms of documented CS-associated ABCC9 and 
identified KCNJ8 mutations. These mutations were engineered into recombinant cDNA clones 
and expressed as functional channels. Macroscopic rubidium (86Rb+) efflux assay experiments 
demonstrate that KATP channels formed with SUR2 and Kir6.1 mutant subunits both result in 
gain of function in KATP activity. Inside-out patch-clamp electrophysiological experiments show 
that there are at least 3 mechanisms by which these mutations alter KATP channel activity, 
viii 
  
including: 1) an SUR2 mutation that indirectly decreases ATP sensitivity by allosteric changes, 
2) a Kir6.1 mutation that increases channel-open probability, and thereby indirectly decreases 
ATP sensitivity, and 3) mutations in SUR2 that increase channel activation in response to 
MgADP. Taken together, CS-associated ABCC9 or KCNJ8 mutations result in enhanced KATP 
activity that underlies the cardinal features of Cantu Syndrome. 
1 
CHAPTER L: INTRODUCTION 
Inwardly-rectifying potassium (Kir) channels are a class of channels generated by 7 gene sub-
families. All Kir channels are made of tetramers of Kir subunits and all require 
phosphatidylinositol 4,5-bisphosphate (PIP2) for channel activity (Huang et al., 1998; Zhang et 
al., 1999). These channels are expressed widely throughout the human body and play important 
roles in regulating membrane potential. Disruption in Kir channel activity is linked to a variety of 
diseases (Pattnaik et al., 2012). The Kir6.X sub-family members generate the pores of adenosine 
triphosphate (ATP) sensitive potassium channels, which is the focus of this project.  
The ATP-sensitive potassium current (IK,ATP)  was first described, in cardiomyocytes, as 
an outward current that is activated during metabolic poisoning and inhibited by ATP (Noma, 
1983). Over the next several years, additional tissues were found to have IK,ATP (Cook and Hales, 
1984; Spruce et al., 1985). Capitalizing on the sensitivity of the current to sulfonylurea drugs, 
Aguilar-Bryan et al. identified and then purified the heteromeric complex of pore and auxillary 
subunits that comprise the ATP-sensitive potassium (KATP) channel (Aguilar-Bryan and Bryan, 
1999). The genes that encode the pore and auxiliary subunits are found in pairs on two different 
human chromosomes. On human chromosome 11p at position 15.1, KCNJ11, which encodes the 
pore-forming Kir6.2 subunit, is directly downstream of ABCC8, which encodes the auxiliary 
subunit SUR1 (Aguilar-Bryan et al., 1995). Conversely, on human chromosome 12p at position 
11.23, KCNJ8, which encodes the pore-forming subunit Kir6.1, is located downstream of 
ABCC9, which encodes the auxiliary subunit SUR2 (Figure 1.1) (Chutkow et al., 1996; Inagaki 
et al., 1995b). 
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Figure 1.1- The genes encoding KATP channel proteins. Cartoon 
representation of human chromosomes 11 and 12, where the genes 
encoding KATP channels are found. Each box represents the gene denoted in 
italics and the name of the encoded protein is indicated above. 
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1.1 KATP Channel Protein Topology 
The pore-forming subunit proteins Kir6.2 and Kir6.1, which are encoded by KCNJ11 and 
KCNJ8, respectively, are members of the inward- rectifying potassium (Kir) channel family. 
Crystallization of the bacterial KcsA potassium channel provided a structural model for the Kir6 
family (Figure 1.2A). The N and C termini orient within the cytoplasm with two transmembrane 
helices connected by a short loop (P-loop), which forms the pore and ion selectivity filter (Doyle 
et al., 1998).  The two Kir6.X family member proteins share ~70% sequence identity (Inagaki et 
al., 1995a).  
KATP channels formed with either Kir6.2 or Kir6.1 exhibit distinct gating and 
conductance. Kir6.2 channels spontaneously activate in the absence of ATP; however, Kir6.1 
channels require the application of activating nucleotides (Kondo et al., 1998). Second, the 
single-channel conductance for Kir6.2, is double that of Kir6.1 conductance (Inagaki et al., 
1995a; Isomoto et al., 1996; Sakura et al., 1995; Yamada et al., 1997). In chimera studies, 
replacing the Kir6.2 extracellular linker and the p-loop with that of Kir6.1 had no effect on 
gating but lowered the unitary conductance, implying that this region determines the unitary 
conductance (Kondo et al., 1998; Kono et al., 2000; Repunte et al., 1999). Conversely, additional 
chimera studies demonstrate that the unique N-terminus and C-terminus of Kir6.2 are necessary 
for spontaneous channel activity. 
The sulfonylurea receptor (SUR) 1 and 2, the KATP auxiliary subunit protein isoforms 
encoded by ABCC8 and ABCC9, respectively, are members of the ATP-binding Cassette (ABC) 
family (Figure 1.1). SUR1 and SUR2 share ~68% sequence identity homology (Inagaki et al., 
1996) and are oriented in the membrane with an extracellular N terminus and a cytoplasmic C 
terminus (Figure 1.2A). As first predicted by hydrophobicity mapping and later confirmed using 
4 
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Figure 1.2- Topology and stoichiometry of the KATP channel complex. A cartoon 
of a KATP channel Kir6.X (blue) and a SURX (yellow) subunit orientation within the 
membrane. The P-loop and the nucleotide binding domains (NBDs) are boxed in red 
and green, respectively (A). The 4:4 stoichiometry of Kir6.X to SURX proteins 
which form the KATP channel complex is depicted in (B). 
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biotinylation assays and immunofluorescence, the SUR protein contains 17 transmembrane 
helices grouped into 3 domains (TMD0-2) connected and followed by cytoplasmic loops that 
form two nucleotide-binding domains (NBD) (Figure 1.2A) (Conti et al., 2001; Tusnady et al., 
1997). SUR2 has two major splice variants, SUR2A and SUR2B (Inagaki et al., 1996; Isomoto et 
al., 1996). Both SUR1 and SUR2 have additional splice sites, but the resulting variants are 
poorly understood (Shi et al., 2005). 
1.2 KATP Channel Stoichiometry/Trafficking/Subunit Pairing 
The size of the purified KATP channel complex suggested that each KATP channel is formed by 
four Kir6.X and four SURX subunits. 1:1 Kir6.2-SUR1 fusion proteins forming functional 
channels provided supporting evidence (Clement et al., 1997) for this hypothesis. The current-
voltage profiles of channels formed with various heteromeric molar ratios of wild-type Kir6.2 
were compared with a strongly rectifying Kir6.2 mutant.  This work provided direct evidence 
that four Kir6.X subunits form the pore (Shyng and Nichols, 1997). The electrophysiological 
properties of KATP channels produced from an engineered fusion construct made of one Kir6.2 
and one SUR1  were identical to those produced by co-expression of Kir6.x and SURX subunits, 
thus confirming  a 4:4 stoichiometry of Kir6.x and SURX subunits forming KATP channels 
(Figure 1.2B) (Shyng and Nichols, 1997). 
The short Arg-Lys-Arg endoplasmic reticulum (ER) retention signals in Kir6.X at the C-
terminus and in SURX between TMD1 and NBF1 are mutually masked in the full complex,, 
allowing for translocation of these subunits to the plasma membrane (Zerangue et al., 1999).  
The retention signal on each Kir6.X and SURX subunit also obligates correct subunit pairing and 
stoichiometry before trafficking to the plasma membrane (Zerangue et al., 1999). However, 
removing the last 30 amino acids from the C-terminus of Kir6.2, which includes the ER-retention 
6 
  
signal, allows Kir6.2 to traffic and function alone on the plasma membrane (Tucker et al., 1997). 
As both pore and auxiliary subunits come in multiple isoforms, the resulting KATP channels can 
be formed with multiple subunit combinations. Studies in heterologous expression systems have 
shown that all combinations are able to traffic and function at the cell membrane (Shi et al., 
2005). Table 1.1 lists subunit combinations that have been identified in native tissues. 
1.3 KATP Channel Activity Regulation 
KATP channels couple cell metabolism and excitability in multiple cell types. Importantly, there 
are a variety of physiological and pharmacological modulators of KATP channels, some of which 
are discussed in detail below.  
1.3.1 Physiological Modulators  
1.3.1.i Nucleotides  
In addition to forming the pore of the channel, the Kir6.X subunits bind inhibitory ATP and 
adenosine diphosphate (ADP) (Mg-free) (Figure 1.3A) (Tucker et al., 1997). Truncation and 
mutagenesis experiments demonstrate that both the N- and C-termini of Kir6.X contribute to the 
ATP-sensitivity (Drain et al., 1998; Koster et al., 1999; Tucker et al., 1998). 
Adenylylimidodiphosphate (AMP-PNP), a non-metabolizable form of ATP, produces an 
inhibitory response identical to that of ATP, indicating that binding, not hydrolysis, of ATP is 
sufficient for KATP inhibition (Inagaki et al., 1995a). The specificity of ATP binding and 
inhibition was validated in photoaffinity labeling experiments. Additionally, numerous 
triphosphates, including: guanine, inosine, cytidine or uridine, fail to inhibit IK,ATP currents in 
both recombinant systems and in native tissues, further supporting the specificity of the KATP 
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Table 1.1- Native KATP Channel Composition in Various Tissues 
TISSUE KATP Channel 
COMPOSITION 
REFERENCES 
BRAIN 
Hippocampus 
Kir6.2/SUR1 
Kir6.2/SUR2 
Kir6.1/SUR1 
Kir6.1/SUR2 
Zawar et al. J Physiol 514: 327-341, 1999 
Hyllienmark, L. and Brismar, T. Journal of Physiol, 496, 
155± 164, 1996 
Fujimura, N. et al. Journal of Neurophysiology, 77, 378± 
385, 1997 
Hypothalamus Kir6.1/SUR1 
Kir6.2/SUR1 
Spanswick, D et al. Nature, 390, 521-525, 1997 
Liss, B. et al. Journal of Physiology 527, 114P-115P, 2000 
 Lee, K. et al. Journal of Physiology 515, 439-452, 1999 
Miki T et al. Nat Neurosci. May;4(5):507-12, 2001 
Ashford, M. L et al.  Pflugers Archives, 415, 479± 483, 
1990 
Brain Stem Kir6.2/SUR1 Karschin, A. et al. Journal of Physiology 509, 339± 346, 
1998 
Trapp, S. and Ballanyi, K., Journal of Physiology, 487, 
37± 50, 1995 
Basal Ganglia 
-Striatum  
-Substantia nigra  
Kir6.1/SUR1 
Kir6.2/SUR2B 
Kir6.2/SUR1 
Lee, K. et al. Journal of Physiology, 510, 441± 453, 1998 
Stanford, I. M. and Lacey, M. G. Neuroscience, 74, 499± 
509, 1996 
Liss, B. et al. Embo Journal, 18,833± 846, 1999 
Schwanstecher, C. and Panten, U. Naunyn Schmiedebergs 
Archives of Pharmacology, 348, 113± 117, 1993 
Roeper, J et al. Journal of Physiology, 430, P130. 1990. 
HEART 
Ventricle 
Kir6.2/SUR2A Babenko AP et al. Circ Res 83: 1132–1143, 1998 
Atrium Kir6.2/SUR1 Flagg TP et al.Circ Res 103: 1458–1465, 2008 
Glukhov AV et al. J Mol Cell Cardiol 48: 152–160, 2010 
Conduction 
System 
Kir6.1/SUR2A 
Kir6.2/SUR2A 
Han X et al.J Physiol 490: 337–350, 1996 
Fukuzaki K et al. J Physiol 586: 2767–2778, 2008 
Kakei M and Noma A. J Physiol 352: 265–284, 1984 
Light PE et al. Cardiovasc Res 44: 356–369, 1999 
PANCREATIC 
BETA CELL 
Kir6.2/SUR1 Inagaki N et al. Science Nov17;270(5239):1166-70, 1995 
SKELETAL 
MUSCLE 
Kir6.2/SUR2A 
Kir6.2/SUR1  
Tricarico D et al. Proc Natl Acad Sci USA 103: 1118–
1123, 2006 
VASCULAR 
SMOOTH  
MUSCLE 
Kir6.1/SUR2B 
Kir6.2/SUR2B 
Isomoto S et al. J Biol Chem 271: 24321–24324, 1996 
Zhang HL and Bolton TB. Br J Pharmacol 118: 105–114. 
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A 
B 
Figure 1.3- Nucleotide Binding and Regulation of the KATP channel. 
The Kir6.X is represented in blue and the SURX subunit is represented 
in yellow. ATP and ADP (No Mg2+), which both bind to the Kir6.X 
subunits to inhibit the channel, are represented by red and green circles, 
respectively. MgADP binds to the Nucleotide Binding Domains (NBDs) 
within the SURX subunit (A). The NBD region is enlarged in the square 
region and the Walker A and Walker B motifs, which are within the 
NBDs, are represented by purple and gray regions, respectively. In these 
Walker motifs ATP and MgADP have been shown to bind. Mg2+ is 
represented by light blue hexagons attached to ADP (B).   
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channel to regulation by ATP (Koster et al., 1999; Lederer and Nichols, 1989; Tanabe et al., 
2000; Tucker et al., 1998).  
Channels composed of Kir6.2 alone, which traffic after truncation of the ER retention 
signal, have decreased sensitivity to ATP inhibition compared to WT channels composed of 
Kir6.2 and SUR1 (Tucker et al., 1997). This finding suggests that SUR subunits also play a role 
in regulating channel activity. Photoaffinity labeling using 8-azido-[α-32P]ATP or 8-azido-[γ-
32P]ATP in cells overexpressing SUR1 demonstrated that ATP binds the SUR subunit directly 
(Ueda et al., 1997). MgADP works at the level of the NBDs in SUR to activate the channel 
(Nichols et al., 1996). Nucleotide binding folds (NBFs), which are conserved in all ABC proteins 
including SURX subunits, contain Walker A and Walker B nucleotide-binding motifs (Figure 
1.3B) (Higgins, 1992). Nucleotide binding sites in SURX were identified by mutagenesis of the 
conserved Walker A and Walker B regions in both NBF1 and NBF2. Free ATP binds to NBF1 
and MgADP interacts with NBF2, but can also alter ATP binding to NBF1 (Ueda et al., 1997).  
Disruption of the NBF2 Walker B motif or linker region within SUR1 completely 
abolishes the activating effect of MgADP, without altering ATP-sensitivity. Conversely, 
mutations at the equivalent positions in the NBF1 Walker B motif only alter activation kinetics 
(Shyng et al., 1997). Expression of SUR1 mutagenized at lysine residue(s) within Walker A 
motifs in NBF1, NBF2 or both, with Kir6.2-WT, produced KATP channels with increased ATP-
sensitivity (no Mg2+) and with MgADP inhibition instead of activation (Gribble et al., 1997). 
Taken together, the Walker A motif in NBF1 and both Walker A and Walker B motifs in NBF2 
are required for MgADP activation of KATP channels (Figure 1.3B). MgADP stimulation differs 
among the SUR isoforms, where SUR1-based channels are more stimulated than SUR2A (Masia 
et al., 2005). The differences in nucleotide-binding affinities among the SUR isoforms may 
10 
  
account for some of the diversity of behavior among the different channel compositions (Matsuo 
et al., 2000).  
1.3.1.ii Phosphorylation 
PKC 
Direct modulation via either the protein kinase C (PKC) pathway or KATP channel activity 
modulates vascular tone. In addition, activation of PKC can decrease KATP channel activity 
indirectly to influence tone. The response of KATP channels to PKC activation could occur 
because: 1) KATP channels are directly regulated by PKC signaling or 2) PKC activation inhibits 
KATP channel indirectly by depleting PIP2 from the membrane. Stable Kir6.1+SUR2B and 
Kir6.2+SUR2B cell lines were used to monitor KATP channel activity response to 
pharmacological activation of PKC in combination with inhibitors of the PKC signaling cascade, 
providing some of the first evidence that Kir6.1 based channels are directly regulated by PKC 
(Quinn et al., 2003).  
Additional engineered chimera studies demonstrated that N- and C-termini of Kir6.1 are 
necessary for PKC regulation. Use of electrophysiology and phosphorylation assays revealed that 
individual intracellular serine residues, which are unique to the C-terminus of Kir6.1, mutated to 
alanine do not prevent PKC inhibition. However, mutating these serine residues simultaneously 
abolishes PKC inhibition of KATP channels. Taken together, several serine residues in the C-
terminus of Kir6.1 are required for direct PKC phosphorylation and inhibition of KATP channel 
activity (Figure 1.4A) (Shi et al., 2008). 
The ability of PKC to inhibit Kir6.1-based KATP channels might suggest that KATP 
channel activation results from dephosphorylation by phosphatases. Electrophysiological data 
11 
  
from isolated rat aortic smooth muscle show that different structural classes of Ca2+-dependent 
protein phosphatase type 2B (PP2B) inhibitors can inhibit IK,ATP.  These results suggest that in 
native tissue, PP2B phosphatase activity can regulate KATP channel activity (Figure 1.4A) 
(Wilson et al., 2000). 
PKA 
At least two studies have shown that KATP channels composed of Kir6.1+SUR2B are activated 
by PKA in a cAMP-dependent manner (Quinn et al., 2004; Shi et al., 2007). There is conflicting 
evidence however about the actual residues phosphorylated by PKA. Quinn et al. concluded that 
a serine residue in Kir6.1 and/or a serine and  a threonine residue in SUR2B are phosphorylation 
sites for PKA(Quinn et al., 2004). On the other hand, Shi et al. made alanine substitutions at 
these residues and found no differences in PKA sensitivity of KATP channel currents, leading 
them to conclude that these sites are not relevant. They went on to identify a single serine residue 
in SUR2B as the only PKA phosphorylation site, which they confirmed by in vitro 
phosphorylation assays (Figure 1.4B) (Shi et al., 2007).   
Despite the debate over which specific Kir6.1 and/or SUR2B residue(s) PKA 
phosphorylates (Quinn et al., 2004; Shi et al., 2007), it is agreed that PKA phosphorylates KATP 
channels directly to regulate vascular tone. There has therefore been an interest in identifying 
potential phosphatase(s) to counter activation of KATP channel after PKA phosphorylation (Orie 
et al., 2009). Dephosphorylation of KATP would inhibit KATP channel activity and, noting that 
Kir6.1+2B activity decreases in high intracellular Ca2+, the Ca2+-dependent phosphatase 
calcineurin was tested as a potential KATP channel phosphatase. Multiple chemically unrelated 
calcineurin inhibitors increase both in vitro phosphorylation of KATP channel subunits and KATP  
12 
  
 
  
A 
B 
Figure 1.4- PKA and PKC signaling pathway regulation of the 
KATP channel. Cartoon of KATP channel regulation by PKC (A) and 
PKA (B)  pathways in which Kir6.1 is depicted in blue surrounded by 
SUR2B in yellow. Red dots depict phosphorylation sites on Kir6.1 c-
terminus or SUR2B as described in the text.  
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channel activity (Figure 1.4B) (Orie et al., 2009). In the presence of a PKA catalytic domain that 
is constitutively active, calcineurin has no effect on KATP channel activity. This observation 
indicates that calcineurin directly dephosphorylates KATP channels to regulate channel activity 
(Orie et al., 2009). 
1.3.1.iii pH 
Increases in intracellular pH result in increases in KATP channel current, in the presence or 
absence of ATP, in isolated rat beta cells (Misler et al., 1989). Further evidence for KATP channel 
pH sensitivity has been obtained from studies on inside-out patches from Xenopus oocytes 
expressing Kir6.2+SUR1 and from isolated mouse cardiomyocytes (Baukrowitz et al., 1999). 
Histidine is the most common amino acid protonated or deprotonated at physiological pH. By 
mutating  each of the 9 intracellular histidine residues in Kir6.2  to amino acids with non-
titratable side chains, a single residue was identified as the pH-sensing residue in KATP channels 
(Baukrowitz et al., 1999). 
1.3.2 Pharmacological Modulation  
In addition to physiological regulation, KATP channel activity is modulated by distinct 
pharmacological agents. The molecular basis and action of these modulators are discussed 
below. 
1.3.2.i  K channel openers (KCOs) 
Diverse classes of drugs called K+ channel openers (KCOs) activate KATP channels by binding to 
the SUR subunits (Inagaki et al., 1996). The ability of individual KCOs to activate channels is 
dependent on the SUR isoform. Whereas SUR1-containing channels are activated specifically by 
diazoxide (Inagaki et al., 1995a), SUR2A -containing channels are effectively activated by all 
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KCOs except diazoxide (Inagaki et al., 1996). SUR2B-containing channels respond to all KCOs 
(Isomoto et al., 1996).  
Synthesis and study of SUR chimera proteins has demonstrated that KCOs such as 
levcromakalim, cromakalim, P1075 and pinacidil appear to bind SUR2 at the intracellular loop 
between TM13 and TM14, with two additional critical residues in TM17, SUR2-L1249 and 
SUR2-T1253. These interactions have been confirmed by the observation that disruption to these 
areas and/or residues alters the activating properties of the KCOs (Moreau et al., 2000; Uhde et 
al., 1999). Diazoxide diverges structurally from that of the majority of KCOs, and its preferential 
binding is thought to be at the NBFs (Shyng et al., 1997). 
1.3.2.ii Sulfonylureas 
 A class of drugs called sulphonylureas also specifically binds the SUR subunit of KATP channels 
but inhibit channel activity (Inagaki et al., 1996). Tolbutamide is an example of a first-generation 
sulfonylurea that binds at TMD2 (Ashfield et al., 1999). Second and third generation, more 
potent, sulfonylureas have been developed; an example is glibenclamide. The binding site of 
glibenclamide also includes TMD2 with additional involvement of a site on the cytoplasmic loop 
between TMD0 and TMD1 (Mikhailov et al., 2001). In general, sulfonylureas are most effective 
at inhibiting SUR1-based channels, less so for SUR2B-, and least effective for SUR2A-based 
channels. 
1.4 KATP Channels in Tissue 
The variation in nucleotide sensitivity, pharmacology and  physiological pairings (Aguilar-Bryan 
et al., 1995; Inagaki et al., 1996) of the Kir6.X and SURX subunits results in diversity of the 
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properties and functional roles of  KATP channels in the tissues in which they are expressed 
(Akrouh et al., 2009; Nichols, 2006). 
1.4.1 Tissue Distribution 
RT-PCR data from a large variety of tissues indicates the pore-forming subunit Kir6.1 is very 
widely expressed (Inagaki et al., 1995c). In contrast, Kir6.2 expression is prominent in pancreatic 
beta cells, brain, heart and skeletal muscle(Inagaki et al., 1995a). In native tissues, SUR1 
subunits only physiologically interact with Kir6.2. Consistent with this finding, SUR1 expression 
is also in pancreatic beta cells, brain, and heart (Inagaki et al., 1995a). Conversely, the SUR2 
subunits pair in native tissue with either Kir6.1 or Kir6.2.  The splice variant SUR2A is found in 
the heart and skeletal muscle where, based on electrophysiology studies, it pairs with Kir6.2. 
Like Kir6.1, SUR2B subunits are expressed widely, and electrophysiological recordings from 
KATP channels in vascular smooth muscle cells appear to reflect the co-assembly of SUR2B with 
Kir6.1(Table 1.1) (Chutkow et al., 1996; Inagaki et al., 1995c). 
1.4.2 Role in Tissue Function  
1.4.2.i  Brain 
KATP channel expression and activity has been reported throughout the nervous system including 
the pituitary gland, basal ganglia, cerebral cortex, hippocampus, basal forebrain, striatum, and 
brain stem (Liss and Roeper, 2001; Seino and Miki, 2003; Yamada and Inagaki, 2005). 
Electrophysiological characterization of KATP channel currents, combined with RT-PCR analysis 
of KATP channel subunit expression, suggests composition of native channels in various regions 
of the brain is quite heterogeneous. Based on radiolabeled glibenclamide studies, KATP channels 
are most abundant in the hypothalamus and substantia nigra pars rectculata (SNr)neurons (Liss 
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and Roeper, 2001; Seino and Miki, 2003; Yamada and Inagaki, 2005). The roles for KATP 
channels in the brain will be discussed below in reference to these regions specifically. 
Hypothalamus 
The hypothalamus, which plays a critical role in glucose homeostasis by regulating counter-
regulatory hormones such as glucagon and catecholamines, relies on glucose-sensing neurons. 
Within these neurons, the electrical firing patterns that lead to the autonomic input to release 
glucagon and catecholamines are regulated by KATP channel activity (Miki et al., 2001).  
Electrophysiological and RT-PCR analysis indicates that Kir6.2 and SUR1 compose the KATP 
channels in these glucose-responsive neurons (Ashford et al., 1990; Miki et al., 2001; Spanswick 
et al., 1997). As brain glucose levels drop, glucose-sensing neurons experience a decrease in the 
intracellular ATP/ADP ratio that activates KATP channels, thereby hyperpolarizing the plasma 
membrane and stimulating autonomic input for glucagon release (Figure 1.5). The release of 
glucagon, from pancreatic alpha cells, stimulates gluconeogenesis and lipolysis to increase blood 
glucose levels (Seino and Miki, 2003).   
SNr 
The basal ganglion contains SNr neurons, which are implicated in the propagation of seizures. 
KATP channels are not active in SNr neurons at rest, allowing for active firing (Yamada and 
Inagaki, 2005). In metabolically stressful conditions, such as hypoxia or hypoglycemia, the 
activity of KATP channels is thought to be critical for protection from seizures. In metabolically 
stressful conditions SNr neurons decrease ATP production, reducing the ATP/ADP ratio, 
activating KATP channels and thereby hyperpolarizing the membrane. Membrane 
hyperpolarization decreases the firing rate of SNr neurons inhibiting GABA release, which is 
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Figure 1.5- The role of KATP channel activity in hypothalamic glucose-
sensing neuron function. Illustrated above is the role KATP channels play in 
hypothalamic glucose-sensing neurons. The KATP channel is depicted in green 
and the voltage gated Ca2+ channel is in orange. 
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hypothesized to slow or prevent propagation (Figure 1.6)(Amoroso et al., 1990; Yamada et al., 
2001). 
1.4.2.ii  Pancreas 
Within the pancreas there are clusters of endocrine cells called islets of Langerhans, of which 
beta cells are the most abundant. Beta cells secrete insulin, an endocrine hormone which helps 
decrease blood glucose levels. KATP channels are expressed abundantly on the plasma membrane 
of beta cells, and are critical for regulating insulin release (Ashcroft and Gribble, 1999). During 
or after a meal, as blood glucose levels elevate, beta cell metabolism increases, which elevates 
the intracellular ATP/ADP ratio, inhibiting KATP channels. Inhibition of KATP channels leads to 
membrane depolarization and activation of L-type Ca2+ channels, which increases Ca2+ entry. 
The increased flux of calcium promotes fusion and release of insulin (Figure 1.7). Once in the 
bloodstream insulin helps decrease blood glucose levels by facilitating glucose uptake into 
muscle (Ashcroft and Gribble, 1999). 
1.4.2.iii Heart 
In the resting state, cardiomyocytes have elevated intracellular ATP/ADP ratios which leaves 
KATP channels generally closed (Koster et al., 2001). While the role of KATP channels in 
regulating heart rhythm or contraction is not fully understood, complete activation of KATP 
channels in the heart can lead to profound shortening of the action potential (Figure 1.8)(Nichols 
et al., 1991). During ischemia, in which a lack of oxygen or glucose disrupts the metabolic 
function of cardiomyocytes, the ATP/ADP ratio decreases, activating KATP channels. Activation 
of KATP channels under these conditions is thought to be cardio-protective since 
hyperpolarization of the membrane will prevent excessive Ca2+ entry, thus preserving 
cardiomyocyte function and promoting cell survival (Bers, 2008).  
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Figure 1.6- Hypothesized role of KATP channels in SNr neuron function. Cartoon 
of the potential role KATP channels play in SNr neurons. The KATP channel is depicted 
in green, the voltage-gated Ca2+ channel is in orange, and yellow circles represent 
GABA. 
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Figure 1.7- The role of KATP channels in beta cell function. Cartoon of the 
role KATP channels play in the pancreatic beta cell, where the KATP channel is 
depicted in green, the voltage-gated Ca2+ channel is depicted in orange and 
insulin is represented by purple circles. 
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Figure 1.8- The role of KATP channels in cardiomyocyte function. 
Cartoon of the role KATP channels play in cardiomyocytes, where the KATP 
channel is depicted in green and the voltage gated Ca2+ channel is depicted 
in orange. 
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1.4.2.iv Skeletal Muscle 
KATP channels are not thought to play a significant role in regulating the electrical activity of 
skeletal muscle in the resting state, but may be crucial during muscle fatigue (Cifelli et al., 2008; 
Gong et al., 2000). KATP channel activity can preserve a polarized membrane potential, 
preventing voltage-dependent Ca2+ entry and decreasing contractility (Gong et al., 2000; Matar et 
al., 2000). After treadmill or swim training, Kir6.2−/− mice, but WT, experience extensive fiber 
damage in muscle. This observation is also consistent with KATP channel activation being 
protective during fatigue (Kane et al., 2004; Thabet et al., 2005). 
There is also evidence that KATP channels play a role in glucose uptake in skeletal 
muscle: 1) sulfonylureas enhance glucose uptake into isolated skeletal muscle (Miki et al., 1998); 
2) Kir6.2-/- mice have increased effectiveness of insulin in lowering blood glucose in the muscle 
versus WT mice (Miki et al., 2002); and 3) muscle from SUR2-/- mice have enhanced insulin- 
stimulated glucose transport in vitro compared to WT (Chutkow et al., 2001). 
1.4.2.v  Smooth Muscle 
 In smooth muscle cells, KATP channel activity is thought to be important for regulating vascular 
tone (Chutkow et al., 2002; Miki et al., 2002). Excised patch clamp experiments on vascular 
smooth muscle cells revealed KATP channels which did not spontaneously open in the absence of 
ATP, a characteristic of nucleoside-dependent Kir6.1 channels (Beech et al., 1993; Kajioka et al., 
1991; Zhang and Bolton, 1996). It is hypothesized that these KATP channels help regulate tone by 
activating in response to a declining ATP/ADP ratio or input from PKA pathways (Figure 1.4B). 
Outward K+ currents through these channels hyperpolarize the membrane, thereby preventing 
Ca2+-entry and leading to vasodilation of the vessel and decreases in contractility (Figure 1.9). In 
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support of this proposed mechanism, treatment with the L-type Ca2+-channel inhibitor, 
nifedipine, protects against the development of vasospasms in SUR2-/- animals (Chutkow et al., 
2002). 
1.5 KATP Channels in Pathophysiology 
KATP channels are widely expressed and provide a finely tuned link between metabolism and 
electrical activity in tissues. Dysregulation of KATP channel activity (gain of function or loss of 
function) results in pathophysiology. Several examples, in which KATP channel dysregulation 
underlies a disease state, are described below.  
1.5.1 Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) 
The first reported clinical characterization of a child with hypoglycemia that failed to improve 
without treatment intervention occurred in 1956 (Cochrane et al., 1956). This disease was later 
termed Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI), and is found in 1 of every 
50,000 live births or up to 1 in every 3,000 live births in familial cases (Stanley and De León, 
2012). Clinically, patients commonly present with increased plasma levels of insulin in 
hypoglycemic conditions along with decreased levels of ketone bodies and free fatty acids 
(Aguilar-Bryan and Bryan, 1999).  
Mutations in KCNJ11 (Kir6.2) or ABCC8 (SUR1) account for nearly 70% of known 
PHHI cases, with the majority of mutations found in ABCC8. Every PHHI-associated KCNJ11 
(Kir6.2) or ABCC8 (SUR1) mutation leads to a decrease in KATP channel activity. This keeps the 
beta cell membrane constantly depolarized and leads to elevated Ca2+ levels and secretion of 
insulin (Figure 1.10)(Remedi and Koster, 2010). 
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Figure 1.9- The role of KATP channels in smooth muscle cell 
function. Cartoon of the role KATP channels play in smooth muscle 
cell function, where the KATP channel is depicted in green and the 
voltage gated Ca2+ channel is depicted in orange. 
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There is no single mechanism by which all PHHI-associated KATP channel mutations reduce 
channel activity. The mechanisms identified to date include trafficking defects, increased ATP 
sensitivity, decreased MgADP activation and Kir6.2 inactivation(Denton and Jacobson, 2012). 
Patients may be treated with the KATP channel opener diazoxide, or high doses of glucose to 
maintain euglycemia (Pinney et al., 2008). However, in extreme cases in which these treatments 
are ineffective, partial or complete removal of the pancreas is necessary(De Leon and Stanley, 
2007). 
1.5.2 Neonatal Diabetes Mellitus 
Phenotypically the opposite of PHHI is a disease called Neonatal Diabetes Mellitus (NDM). Also 
a condition commonly diagnosed in infants less than six months old, NDM patients present with 
hyperglycemia and hypoinsulinemia. NDM incidence is estimated to be ~1 in every 100,000-
300,000 births (Naylor et al., 2011). It results from disruption in genes encoding critical proteins 
for beta cell function including missense mutations in genes encoding proteins in the metabolic 
pathway or involved in insulin production or secretion (Remedi and Nichols, 2009). The most 
common monogenic cause of NDM is gain of function in KATP channel activity due to mutations 
in either KCNJ11 (Kir6.2) or ABCC8 (SUR1) (Naylor et al., 2011). Despite elevated ATP/ADP 
ratios, which results from increased glucose metabolism, the gain of function in KATP channel 
activity prevents channel inhibition. Because KATP channels remain open, the membrane remains 
hyperopolarized, leading to cessation of beta cell secretion of insulin (Figure 1.11) (Koster et al., 
2000).   
 NDM-associated KATP channel mutations are scattered throughout the Kir6.2 and SUR1 
proteins (Denton and Jacobson, 2012), with multiple underlying molecular mechanisms. Kir6.2 
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A 
B 
Figure 1.10- The role of KATP channels with decreased activity in the 
function of beta cells in PHHI patients. Cartoon of the role KATP channels 
play in normal beta cell function (A) or with decreased KATP channel activity 
as found in PHHI patients (B).  The KATP channel is depicted in green and 
the voltage-gated Ca2+ channel is depicted in orange. 
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mutations have most commonly been shown to give rise to increased channel activity by 
increasing the intrinsic open probability of the channel or by decreasing the affinity or binding of 
inhibitory ATP (Koster et al., 2008b). Similarly, mechanisms for SUR1 mutations also result in 
overactive KATP channels, but enhanced affinity for MgADP and altered nucleotide hydrolysis at 
the NBDs can additionally be responsible (Denton and Jacobson, 2012).   
Originally NDM patients were treated with insulin injections as a means of managing 
their blood glucose levels, but understanding the molecular basis of KATP channel-dependent 
NDM cases has allowed for better/simpler treatment (Babenko et al., 2006; Sagen et al., 2004; 
Zung et al., 2004). Now, instead of insulin injections, patients are typically administrated 
sulphonylureas tablets orally, as an easier and more targeted treatment that directly inhibits the 
overactive KATP channels. Additionally, sulfonylureas typically result in more regulated 
glycemic control, relative to insulin therapy (Koster et al., 2008a). However, it should be noted 
that in patients with mutations that result in extremely overactive KATP channels sulfonylureas  
are not always effective (Remedi and Koster, 2010).  
1.5.3 Cantu Syndrome 
 A disease more recently proposed to be associated with defective KATP channels is Cantu 
Syndrome (CS), a rare and complex disorder. In the first description of this disorder, reported by 
Dr. Cantu in 1982, four patients presented with hypertrichosis and dental abnormalities, 
comparable to that seen in patients with hypertrichosis universalis and/or congenital 
hypertrichosis lanuginose. Additional skeletal abnormalities in these patients establish CS as a 
unique disorder (Cantu et al., 1982). The heritability of CS in both males and females from  
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B 
Figure 1.11- The role of overactive KATP channels in the beta cell function 
of NDM patients. Cartoon of the role KATP channels play in normal beta 
function (A) or the role of overactive KATP channels play in the beta cell 
function of patients with NDM (B). The KATP channel is depicted in green and 
the voltage-gated Ca2+ channel is depicted in orange.  
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 asymptomatic parents originally suggested that it can be an autosomal recessive disease (Cantu 
et al., 1982). However, a familial case in which a father with CS passed it to his son, made 
autosomal dominance more likely (Lazalde et al., 2000). 
The  number of CS patients described in the literature to date totals ~50 and the clinical 
hallmarks have expanded to include: hypertrichosis, macrosomia, macrocephaly, coarse facial 
appearance, cardiomegaly, and skeletal abnormalities (Nichols et al., 2013). Additional 
symptoms present in subsets of patients includes patent ductus arteriosus, lymphedema, heart 
vavular anomalies, and congenital hypertrophic cardiomyopathy (Grange et al., 2014). The fact 
that hypertensive patients treated with (KCOs) such as Minoxidil (Mehta et al., 1975), diazoxide 
(Goldberg, 1988), or pinacidil (Koblenzer and Baker, 1968) can develop similar features, 
including hypertrichosis and structural defects in the heart, led to the hypothesis that CS could be 
a result of dysregulated potassium channel activity (Grange et al., 2006).  
It was not until 2012, however, when the genetic analysis of two separate CS patient 
cohorts determined that the majority have mutations in ABCC9 (SUR2), that the K+ channel 
dysregulation hypothesis was investigated. Harakalova et al. expressed Kir6.2-WT with three of 
the identified SUR2 mutations and found that KATP channel activity was increased (Harakalova 
et al., 2012). The data presented in the following chapters represent the first reports of KCNJ8 
mutations which result in CS, and the mechanisms underlying the functional effects of these 
mutations.  Additionally included is the first molecular account and detailed mechanistic study of 
how the gain of function in KATP channel activity arises from CS-associated SUR2 mutations.  
KATP channels are highly regulated and are expressed throughout the body, and these 
channels primarily function to link cell metabolism and cell excitability. This body of work is 
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focused on determining the mechanism(s) by which identified mutations in Kir6.1 and SUR2, 
found in CS-patients, alter KATP channel activity. CS patients with Kir6.1 or SUR2 mutations 
have overlapping symptoms, and the results presented imply that the gain of function in KATP 
channel activity is causal. This work underscores the intricate role KATP channels play in tissues 
and how minor changes in channel activity can have profound effects on disease presentation. 
Understanding the impact these mutations have on channel activity should provide insight into 
how a gain of function in KATP channels activity results in the various pathophysiological 
consequences of CS and, more importantly, guide future efforts focused on inhibiting these 
overactive channels as a treatment option for patients.  
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CHAPTER W: METHODS 
Mutagenesis and Heterologous Expression of KATP Channels 
The Quick Change II Site-Directed Mutagenesis kit (Agilent Technologies) was used to engineer 
SUR2 mutations into ratSUR2A-pCMV6, Kir6.1 mutations into ratKir6.1-pcDNA3.1, and Kir6.2 
mutations into mouseKir6.2-pcDNA3.1. Mutations were confirmed by direct sequencing of the 
SUR2 or Kir6.X coding regions.  
For channel expression, COSm6 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum, 105 units/L penicillin, and 100 
mg/L streptomycin. At 60-70% confluence, cells were transfected with the relevant plasmids 
using FuGENE6 transfection reagent (Promega). For experiments with homomeric CS mutant 
channels, cells were co-transfected with pCDNA3.1‐mouseKir6.2-WT (0.6 µg) and wild-type 
(WT) or mutant pCMV6-ratSUR2A (SUR2) (1 µg). For experiments on heteromeric channels, 
cells were co-transfected with mouseKir6.2-WT, ratSUR2-WT, and mutant SUR2 at ratios of 
0.6:0.5;0.5 (w:w:w). Cells transfected with GFP-pcDNA3.1 served as controls. A small amount 
of GFP cDNA was included to allow for identification of GFP-expressing transfected cells 
during electrophysiology experiments.  
Macroscopic 86Rb+ Efflux Assays 
Cells were incubated overnight at 37°C in DMEM containing 1 µCi/mL 86RbCl  (PerkinElmer 
Life Sciences), and then incubated  in Ringers solution (mM: NaCl 118, HEPES 10, NaHCO3 25, 
KCl 4.7, KH2PO4 1.2, CaCl2 2.5, MgSO4 1.2, adjusted to pH 7.4 with NaOH) in (1) the absence 
(basal) or (2) the presence of 2.5 mg/mL oligomycin and 1 mM 2‐deoxy‐d‐glucose (metabolic 
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inhibition), (3) the presence of SUR1 or SUR2-specific K+ channel openers diazoxide or 
pinacidil or (4) a combination of metabolic inhibition and pinacidil, to achieve maximal channel 
activation. Subsequently, at selected time points (2.5, 5, 7.5, 15, 25, and 40 minutes), the solution 
was collected and replaced with fresh solution. Upon completion of the assay, cells were lysed 
with 2% SDS and collected, and the radioactive 86Rb+ in these samples was measured. 86Rb+ 
efflux is expressed as a fraction of total content. An inactivating, KATP-independent,  
conductance was assumed to be present in all 86Rb+ efflux experiments, and apparent rate 
constants for the KATP-independent 
86Rb+ efflux were obtained from GFP transfected cells using 
the equation:  
[1]   Rb efflux = {1 − ∗∗ . } 
where k1 and k-1 are the apparent activation and inactivation rate constants. KATP-dependent 
86Rb+ 
efflux was also assumed to activate and inactivate with time and was obtained using the 
equation: 
[2]  Rb efflux = {1 − ∗∗  ∗ ∗!. } 
where k1 and k-1 are the rate constants for KATP independent pathways (obtained from GFP-
transfected cells by Equation 1), k2 and k-2 are the activation (k2) and inactivation (k-2) rate 
constants for KATP-specific K
+ conductance. k2 is then assumed to be proportional to the number 
of active KATP channels.  
86Rb+ efflux experiments were also carried out in the presence of MI with the addition of 
10 µM glibenclamide. In these experiments, the k-2 parameter was assumed to be the same for 
each construct and all KATP-dependent fluxes were fitted simultaneously on any given day and 
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under any given condition. To account for day-to-day variability, k1 was determined in mock 
transfected cells for each condition (Basal, MI, PIN, MI+PIN, and MI+GLIB), and incorporated 
into the equation to estimate the KATP-dependent k2 for each construct. 
Excised Patch Clamp  
After 24-48h, transfected cells that fluoresced green under UV light were selected for analysis by 
excised patch clamp experiments at room temperature. For experiments, cells were placed in a 
perfusion chamber that allowed for the rapid switching of solutions. Kint solution (mM: KCl 140, 
HEPES 10, and EGTA 1, to pH 7.4) was used as the standard pipette (extracellular) and bath 
(cytoplasmic) solution in these experiments. ATP or ADP was added as indicated. The 
appropriate amounts of MgCl2 to be added in each Mg
2+-nucleotide containing solution to attain 
0.5 mM free Mg2+ were calculated by means of the CaBuf program (KU Leuven). Membrane 
patches were voltage-clamped using an Axopatch 1D amplifier (Molecular Devices), and 
currents were recorded at −50 mV (pipette voltage, +50 mV) in the on-cell and inside-out 
excised patch configurations. Data were typically filtered at 1 kHz and digitized at 5 kHz with a 
Digidata 1322A (Molecular Devices) A-D converter. pClamp and Axoscope software (Molecular 
Devices) were used for data acquisition. For ATP inhibition, [ATP]-response relationships (Fig. 
4) were fitted by equation 3: 
[3]     "#$ = {1 + &
'()*+
,-
.
/
}0 
where Irel (relative current) is the current in the presence of a given concentration of ATP relative 
to current in zero ATP, Ki is the apparent ATP inhibition constant, and H is the Hill coefficient. 
For PIP2 activation experiments, an ammonium salt of L-α-phosphatidylinositol-4,5-
bisphosphate from Porcine Brain (Brain PI(4,5)P2) (Avanti Polar Lipids) was dissolved in KINT  
to make a 5 µg/µL working solution. For each patch, we estimated the relative Po by dividing the 
maximum steady-state current in zero ATP by the maximum steady-state current in PIP2.  
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CHAPTER Z: CANTU SYNDROME RESULTING FROM ACTIVATING MUTATION IN 
THE KCNJ8 GENE 
Cooper PE et al. 2014 
3.1 Introduction 
In collaboration with Heiko Reutter we screened KCNJ8 in an ABCC9 mutation-negative patient 
who also exhibited clinical hallmarks of CS (hypertrichosis, macrosomia, macrocephaly, coarse 
facial appearance, cardiomegaly, and skeletal abnormalities). A de novo missense mutation 
encoding Kir6.1[Cys176Ser] was identified in the patient. Kir6.1[p.Cys176Ser] channels 
exhibited markedly higher activity than wild-type channels, as a result of reduced ATP 
sensitivity, whether co-expressed with SUR1 or SUR2A subunits. Our results identify a novel 
causal gene in CS, and also demonstrate that the cardinal features of the disease result from gain 
of KATP channel function, not from a Kir6-independent SUR2 function. 
3.2 Methods  
All genetic analysis and patient assessments were carried out in collaboration with 
Heiko Reutter’s group. 
3.3 Results 
Case study 
The clinical phenotype of the proband at the age of 3 months was originally described by Engels 
et al. (Engels et al., 2002). Following the realization that this CS patient harbored a distinct 
molecular basis, we have now carried out a detailed reevaluation of the patient at the age of 13 
years. The patient shows key clinical hallmarks of CS, including congenital hypertrichosis, 
macrosomia at birth, macrocephaly, coarse facial appearance, cardiomegaly, skeletal 
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abnormalities, and developmental delay. At the time of reevaluation, he also had excessive 
gingival hyperplasia (Figure 3.1C).  
Echocardiography at 13 years of age showed normal biventricular function with signs of 
noncompaction of the left ventricular apical myocardium, sonography of parenchymal abdominal 
organs was within the normal range, as were ECG and 24 hr blood pressure measurements. The 
patient's weight was 41 kg (25.–50. centile), height was 144 cm (10.–25. centile) and BMI was 
19.5 (+0.3 SDS). He appeared disproportionate with a sitting height of 76 cm, arm span of 
151.5 cm (10–25th centile) and arm span: height ratio >97th centile. His chest X-ray showed the 
same broadening of ribs as initially reported (Engels et al., 2002). X-ray of his left hand showed 
his bone age to be 10½ years at 13 years of age, corresponding to a delay of 2½ years. 
Laboratory studies showed essentially undetectable serum IGF-1 levels (<25 ng/ml, Ref. value 
131–690) and a relatively low IGFBP3 value of 1.4 μg/ml (Ref. value 2.6–8.9). Arginine 
tolerance and clonidine test revealed absolute growth hormone (GH) deficiency (basal and all 
stimulated GH concentrations were below 1.0 ng/ml). GHRH testing resulted in subnormal GH 
secretion (max. GH 2.8 ng/ml). 
Comparison of the present case with recently published CS patients carrying ABCC9 
mutations (Harakalova et al., 2012; van Bon et al., 2012) shows that the present patient exhibits 
all clinical hallmarks of CS, as well as 10/12 CS associated facial/cranial features; 2/5 cardiac 
features; 7/17 skeletal abnormalities, visible on radiographic studies; and 3/15 additional 
previously reported CS-associated features.  
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Figure 3.1- Gain-of-function KCNJ8 mutation Kir6.1[Cys176Ser]underlies Cantu 
syndrome. A: Sequence chromatogram of patient and unaffected parents’ genomic 
DNA confirms de novo g.21,919,406A>T transition mutation in the patient, which is 
absent in the mother and father. B: Ribbon diagram of two of the four Kir6.1 subunits 
that form the K+-selective pore in KATP, based on the crystal structures of KirBac1.1 
(PDB ID: 1BL8) and cytoplasmic domain of Kir3.1 (PDB ID: 1N9P). Shown are 
Kir6.1 residues mutated in CS (Cys176Ser), and reported in association with the J-
wave syndrome (p.Ser422Leu).C: Clinical phenotype of the patient. Photographs of 
the patient at 13 years reveal extensive hypertrichosis, macrocephaly, coarse facial 
appearance, long arm- and torso-to-height ratio, and gingival hyperplasia with 
thickened lips.   
 
37 
  
Genetic analysis 
To date, mutations in ABCC9 are the only known genetic cause of CS (Czeschik et al., 2013; 
Harakalova et al., 2012; van Bon et al., 2012). In our initial study, we found that nine out of 12 
patients diagnosed with CS carry missense mutations in ABCC9 (van Bon et al., 2012).We 
performed Sanger sequencing of the three coding exons of KCNJ8 in the three unexplained 
patients, including the present case. KCNJ8 was chosen as the most promising candidate gene 
because of the functional considerations stated above. The study was approved by the local 
ethics committees, and all participating patients gave written informed consent. Parental consent 
was given on behalf of patients younger than 18 years of age; the study was explained to children 
capable of giving assent, and they provided oral assent.  
In the proband, we identified a mutation Chr12(GRCh37):g.21919406A>T 
(NM_004982.2:c.526T>A), in the KCNJ8 gene, encoding a missense mutation (Cys176Ser) in 
the Kir6.1 protein (Figure 3.1).We did not observe the mutation in any of 2,096 in-house 
exomes, nor is it reported in any of 6,503 individuals from the exome variant server (Exome 
Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA 
(URL: http://evs.gs.washington.edu/EVS/) [March 2014]). The variant has been deposited in the 
LOVD 3.0 (http://databases.lovd.nl/). The  mutation is predicted to be “deleterious” by SIFT 
(score 0.03), and probably damaging by PolyPhen2 (score 1.0). The affected amino acid is fully 
conserved in both mammalian Kir6.1 and Kir6.2 proteins, suggesting a key role in channel 
function. Paternity was proven and sample mix-up excluded by STR marker analysis. The 
mutation was not present in maternal or paternal DNA and hence was presumed to have arisen de 
novo. Primer sequences and PCR conditions are available upon request.  
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Functional analysis of KCNJ8 mutations 
To assess the effect of the Cys176Ser mutation on channel activity, mutant and wild type KCNJ8 
(Kir6.1) cDNAs were co-transfected with ABCC8 (SUR1) or ABCC9 (SUR2A) cDNAs. Channel 
activity was assessed under normal metabolic conditions, in metabolically inhibited conditions 
(mimicking tissue ischemia), and in the presence of pharmacological potassium channel openers 
(KCOs), using 86Rb+ efflux assays (see Methods). We also examined the channel activity 
resulting from Kir6.1[Ser422Leu], a mutation reported in several studies to be associated with J-
wave abnormalities in the electrocardiogram (Barajas-Martinez et al., 2012; Medeiros-Domingo 
et al., 2010). As shown in Figure 3.2 and 3.3, very similar fluxes were measured for WT Kir6.1 
and Ser422Leu channels. Measurable basal conductance was present for WT Kir6.1 with SUR1, 
but only MI- or KCO-stimulated fluxes were present for WT plus SUR2A. In contrast, 
significant fluxes were present for Kir6.1[Cys176Ser] with SUR1, and both MI- and KCO-
stimulated fluxes were higher for each Kir6.1[Cys176Ser]/SUR combination. These experiments 
establish that the Cys176Ser mutation indeed causes a gain- of-function in the Kir6.1 channel, 
leading to markedly enhanced channel activity even under basal metabolic conditions, in co-
expression with either SUR1 or SUR2A subunits.  
 To gain further insight to the mechanism by which the mutation enhances channel 
activity, we turned to patch-clamp experiments. The majority of KATP channels in vivo are 
probably formed as homomeric Kir6.1 tetramers or Kir6.2 tetramers, although there is evidence 
that heteromeric Kir6.1/Kir6.2 combinations may also be present in cardiac (Bao et al., 2011) 
and smooth (Flagg et al., 2010; Insuk et al., 2003) muscle, for instance. Since the original 
cloning and expression of KATP subunit genes, it has been clear that Kir6.1 channels are 
experimentally considerably more labile in excised patches than are Kir6.2 channels, and channel  
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Figure 3.2- Increased channel activity in basal and stimulated conditions in intact cells 
expressing Kir6.1[C176S]-containing KATP channels. Relative efflux of 86Rb+ as a 
function of time in basal conditions (left), in the presence of potassium channel openers 
(center), or in metabolic inhibition (right) for reconstituted wild-type and mutant KATP 
channels (with SUR1 (above) or SUR2A (below)), and untransfected controls (mean + 
s.e.m., from 4-6 experiments). Data were fit with a double-exponential equation to obtain 
rate constants for KATP-dependent efflux, k2 (see Methods). Lines show mean fitted equations  
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Figure 3.3- Increased relative efflux in basal and stimulated conditions in 
intact cells expressing Kir6.1[C176S]-containing KATP channels. Relative 
efflux rate constants for KATP-dependent 
86Rb+efflux (k2)of 
86Rb+ as a function of 
time in basal conditions (black), in the presence of potassium channel openers 
(white), or in metabolic inhibition (gray) for reconstituted wild-type and mutant 
KATP channels (with SUR1 (A) or SUR2A (B)), and untransfected controls in 
basal conditions relative to metabolic inhibition (MI) for WT and mutant 
KATP channels  (mean ± s.e.m., from 4 to 6 experiments). *P < 0.01 compared 
with the wild-type KATP by unpaired Student's t-test.  
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activity rapidly runs down in the absence of Mg-nucleotides, complicating the assessment of 
both inhibitory nucleotide sensitivity and intrinsic open probability of the channel. In the patient, 
the mutation is present in only one allele and since the active channels are tetramers, expressed 
KATP channels in native cells will therefore be expected to consist of a mixture of both 
Cys176Ser and wild-type Kir6.1 or Kir6.2 subunits. To take advantage of this fact and 
additionally test the effect of heterozygosity, we co-expressed a 1:1 mixture of wild-type or 
mutant Kir6.1 cDNAs with wild-type Kir6.2 and SUR2A cDNAs (Figure 3.4). 
These mixtures generated measurable fluxes in tracer studies and stable currents in 
excised patches. From these measurements it is evident that enhanced channel activity in intact 
cells expressing Cys176Ser (Figure 3.4) result from reduced ATP sensitivity (Figure 3.5B and 
3.5C). We cannot formally rule out the possibility that altered trafficking and increased plasma 
membrane channel density may also play a role, but such effects have not previously been 
described for mutations in Kir channel pore regions. The findings indicate that the heterozygous 
Cys176Ser mutation in Kir6.1 will over activate any native KATP channels in which it is present. 
The results are very consistent with the effects of the exact equivalent, and well-studied 
mutation, Cys166Ser in Kir6.2, which reduces ATP sensitivity of expressed channels by ∼50-
fold (Loussouarn et al., 2000; Tucker et al., 1998). Additional mutations at this residue in Kir6.2, 
which also cause marked GOF, have been identified as causal in the most severe form of 
neonatal diabetes that is associated with developmental delay and epilepsy (Gloyn et al., 2006). 
3.3 Discussion 
CS was first characterized as such by J.M. Cantú in 1982 (Cantu et al., 1982). A genetic cause 
was recently reported (Harakalova et al., 2012; van Bon et al., 2012), with coding mutations 
identified in the ABCC9 gene, in 25 out of 30 patients. The present study reveals that a 
heterozygous mutation in KCNJ8, encoding the Kir6.1 pore-forming subunit of KATP channels, 
can also cause CS. A recent study identified a different mutation in KCNJ8 (encoding Val65Met)  
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Figure 3.4- Increased channel activity in basal and stimulated conditions in 
reconstituted heteromeric KATP channels containing Cys176Ser subunits.               
A) Relative efflux of 86Rb+ as a function of time in basal conditions (left), in the 
presence of potassium channel openers (center), or in metabolic inhibition (right) for 
heteromeric Kir6.1/Kir6.2 or Kir6.1[Cys176Ser]/Kir6.2 plus SUR2A KATP channel-
expressing cells, and untransfected control cells (mean + s.e.m., from 3 experiments). 
Data were fit with a double-exponential equation to obtain rate constants for KATP-
dependent efflux, k2 (see Methods). Lines show mean fitted equations. B) Rate 
constants for KATP-dependent 
86Rb+ efflux (k2) in basal conditions (black) and in 
metabolic inhibition (MI) (gray) from COS cells expressing heteromeric Kir6.1/Kir6.2 
or Kir6.1[Cys176Ser] (C176S)/Kir6.2 plus SUR2A KATP channels. 
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Figure 3.5- Reduced ATP-sensitivity of reconstituted heteromeric KATP channels 
containing Kir6.1[Cys176Ser] subunits. A: Rate constants for KATP-
dependent86Rb+ efflux (k2) in basal conditions and in metabolic inhibition (MI) from COS 
cells expressing heteromeric Kir6.1/Kir6.2 or Kir6.1[Cys176Ser] (C176S)/Kir6.2 plus 
SUR2A KATP channels. B: Representative currents recorded from inside-out membrane 
patches from COS cells expressing heteromeric Kir6.1/Kir6.2 or Kir6.1[Cys176Ser] 
(C176S)/Kir6.2 plus SUR2A KATP channels at −50 mV in Kint solution (see Supplementary 
information). Patches were exposed to differing [ATP] and baseline current was determined 
by exposure to 5 mM ATP. C: Steady-state dependence of membrane current on [ATP] 
(relative to current in zero ATP (Irel)) for wild-type and Cys176Ser-containing channels. 
Data points represent the mean ± s.e.m. (n = 6–8 patches). The fitted lines correspond to 
least squares fits of a Hill equation. *P < 0.01 compared with the wild-type KATP by 
unpaired Student's t-test. 
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in another CS patient (Brownstein et al., 2013), although there was no functional characterization 
of mutant channels. The marked GOF in expressed Kir6.1[Cys176Ser] channels (Figures 3.1 
and 3.2), which mirrors the well-studied properties of Kir6.2 channels with mutations at the 
equivalent Cys166 residue (Gloyn et al., 2006; Loussouarn et al., 2000; Trapp et al., 1998; 
Tucker et al., 1998), clearly establishes Cys176Ser as a severe GOF. Thus GOF mutations in 
both ABCC9 and KCNJ8 cause essentially the same hallmark CS features in the affected patients 
indicating that these features all result from GOF of KATP channels formed from these subunits. 
This is a subtle but critical conclusion: previous studies (Aggarwal et al., 2010; Stoller et al., 
2010) have raised the possibility of Kir6-independent roles of SUR2 proteins and, in the absence 
of the present findings, some or all of the features of CS could conceivably have arisen from 
non-channel functions of the SUR2 protein.  
The results underscore the key role of KATP channels in coupling cell membrane potential 
with diverse tissue functions. Our results are consistent with the finding that vascular smooth 
muscle contractility is markedly decreased in the presence of KATP channel openers (Flagg et al., 
2010) and in transgenic mice expressing mutant Kir6.1 subunits with reduced sensitivity to 
inhibitory ATP (Li et al., 2013). These observations potentially explain some of the key findings 
in CS, including patent ductus arteriosus, as was present in the patient reported here.  
A novel finding is the puzzling combination of biochemical signs of absolute growth 
hormone (GH) deficiency, yet postnatal growth with height within the normal range. Pituitary 
GH secretion is mainly regulated by two hypothalamic neuropeptides. GHRH stimulates GH 
release, whereas somatostatin inhibits GH secretion (Muller et al., 1999). In addition, a number 
of GH-releasing peptides are able to modulate GH release. The rat pituitary expresses several Kir 
channel alpha-subunits, including Kir6.1 (Wulfsen et al., 2000). GHRP-2, one member of the 
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GH-releasing neuropeptides, exerts its GH secretory effect through a reduction in potassium 
current (Xu et al., 2002). It is therefore tempting to speculate that GOF mutations in pituitary 
KATP channels exert an opposite effect on GHRH stimulation, leading to resistance to 
hypothalamic induction of GH release. On the other hand, GH insufficiency yet normal growth 
can only be explained by a concurrent stimulation of long bone growth. Previous animal models 
indicated that a significant part of postnatal growth depends on local growth stimulation in the 
growth plate rather than on the effect of circulating IGF-1 (Ohlsson et al., 2009; Yakar et al., 
1999), although understanding of molecular mechanisms at the growth plate leading to long bone 
growth is incomplete. It is not yet clear whether ABCC9 mutation patients exhibit similar 
deficiencies, and if not, this finding may be a KCNJ8-specific outcome, or may be unrelated to 
CS. 
A common KATP pathway can account for direct overlap of CS features resulting from 
mutations in ABCC9 and KCNJ8, as well as with features resulting from overexposure to 
minoxidil and other KATP channel openers (Avatapalle et al., 2012; Kaler et al., 1987; Nguyen 
and Marks, 2003; Shanti et al., 2009). However, this does not provide an obvious explanation for 
many CS features. For instance, macrocephaly and characteristic facial features, as well as 
skeletal abnormalities are present in both ABCC9 and KCNJ8 patients. However, while KATP 
channels generated by these subunits have been reported in human chondrocytes (Mobasheri et 
al., 2012; Rufino et al., 2013) and osteoblasts (Kawase et al., 1996), their role in maturation and 
proliferation remains unknown, and the cellular pathway involved is not obvious. Interestingly, 
minoxidil has been reported to induce pseudoacromegalic features in the absence of elevated GH 
or IGF-1 (Nguyen and Marks, 2003). Similarly, epicanthal folds and deep plantar creases might 
result from KATP gain-of-function, but the underlying cause is unknown. Finally, pericardial 
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effusion, polydramnios and lymphoedemia, potentially all related problems of membrane barrier 
breakdown, are unexplained. SUR2/Kir6.1 KATP channels have been reported in epithelial cells 
(Bardou et al., 2009), but again, cellular pathways are unexplained.  
Finally, we would note that several other studies have reported a different mutation 
(p.Ser422Leu) in the Kir6.1 protein to be associated with ‘early repolarization syndrome’ (ERS), 
characterized by abnormalities in the J-point of the electrocardiogram (Delaney et al., 2012; 
Haissaguerre et al., 2009). Recent studies have reported that this p.Ser422Leu mutation enhances 
channel activity (Medeiros-Domingo et al., 2010), by reducing ATP-sensitivity (Barajas-
Martinez et al., 2012). If so, there is a clear inconsistency: neither J-wave abnormalities nor other 
arrhythmias have been reported in CS patients, and none of the CS features have yet been 
reported for ERS patients. Our own data (Figure 3.2) indicate that, in recombinant COS cells, 
p.Ser422Leu does not affect Kir6.1-dependent KATP channel activity, consistent with the recent 
recognition that this mutation may actually represent a common variant (~4%) in Ashkenazim 
subjects, and not clearly associated with ERS (Veeramah et al., 2014). 
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CHAPTER f: DISEASE CAUSING SLIDE HELIX RESIDUE MUTATION IN KIR6.1 AND 
KIR6.2 
4.1 Introduction 
While all previous reports of CS-associated mutations are in the ABCC9 gene, a CS patient with 
a KCNJ8 mutation, encoding V64M in the Kir6.1 subunit, was described by Brownstein et al. in 
2013, although no functional support for this mutation causing any change in channel activity 
was provided. Interestingly, a previously identified mutation at the equivalent position in Kir6.2 
(V64L), was reported to have no effect on KATP channel a. Here, I directly compare these two 
published mutations: valine to methionine and valine to leucine in the equivalent positions in 
Kir6.1 (V65) and Kir6.2 (V64), co-expressed with SUR1 or SUR2A. Using macroscopic 
rubidium (86Rb+) efflux assays, I show that, compared to WT channels, both Kir6.1-V65M and 
Kir6.2-V64M enhance KATP activity, but channels formed with Kir6.1-V65L and Kir6.2-V64L 
are unaffected. Additionally, Kir6.2-V64M-based channels decrease ATP sensitivity and PIP2 
activation, but V64L-based channels do not. Taken together, these data provide functional 
support for the notion that CS-associated Kir6.1-V65M mutation leads to overactive KATP 
channels. More specifically, the mechanism of this GOF is a result of the valine-to-methionine 
substitution increasing channel Po and thereby indirectly decreasing ATP inhibition. These 
findings are consistent with a causal involvement of this mutation in CS. 
4.2 Results 
Kir6.1-V65M, but not Kir6.1-V65L, forms overactive KATP channels paired with SUR1 or SUR2 
To examine KATP channel activity in intact cells, I performed rubidium (
86Rb+) efflux assays (see 
Methods) under three metabolic conditions: basal; metabolic inhibition (MI), which prevents 
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ATP production; or in the presence of SURX-specific potassium channel openers diazoxide 
(SUR1) or pinacidil (SUR2). Kir6.1-WT, Kir6.1-V65M and Kir6.1-V65L were each 
homomerically expressed with SUR1 (Figure 4.1). Under basal and diazoxide conditions Kir6.1-
V65M based channels exhibited significantly higher 86Rb+ efflux rate compared to WT channels, 
while Kir6.1-V65L channels efflux rates were comparable to WT (Figures 4.1A and 4.1B).  
Maximal activation, estimated under MI conditions, comparable for Kir6.1-V65M, V65L and 
Kir6.1-WT based channels, implying no differences in expressed channel densities (Figure 
4.1C).  
When paired with SUR2A, basal fluxes through Kir6.1-WT, Kir6.1-V65M and Kir6.1-V65L 
were undistinguishable (Figure 4.2A), presumably due to lower activation of SUR2 by MgATP 
or MgADP compared to SUR1(Masia et al., 2005). However, when KATP- specific fluxes were 
activated in pinacidil or MI conditions, Kir6.1-V65M but not Kir6.1-V65L fluxes were 
significantly increased compared to WT channels (Figure 4.2B and 4.2C). These trends are 
consistent with Kir6.1-V65M causing a GOF, but Kir6.1-V65L having WT-level KATP channel 
activity when paired with SUR1 or SUR2 (Figures 4.1 and 4.2).  
Kir6.2-V64 mutated to methionine or leucine produces comparable functional changes to Kir6.1-
V65M or L mutations 
Kir6.1 (V65) and Kir6.2 (V64) are localized within an identical sequence region in the slide 
helix (Inagaki et al., 1995c). Therefore, it is likely the role this valine residue plays in gating is 
conserved between each channel. In the basal condition, whether expressed with SUR1 or SUR2, 
Kir6.2-V64M formed channels with increased efflux rates compared to wild type channels, but 
Kir6.2-V64L-based channels exhibited comparable activity to WT (Figure 4.3A and 4.4A).  
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Figure 4.1- Homomeric Kir6.1-V65M–but not Kir6.1-V65L–expressed with SUR1 
increases KATP channel activity under basal conditions and in the presence of diazoxide 
in intact cells.  Cumulative 86Rb+ efflux, as a function of time, was measured in GFP-
transfected control cells (black symbols), and in cells transiently expressing SUR1 plus 
Kir6.1-WT (white triangles), Kir6.1-V65M (blue squares) or Kir6.1-V65L (light grey 
circles). Experiments were done in basal conditions (A), in the presence of the K+ channel 
opener diazoxide (B), or metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (C). 
The data represents the means + S.E.M. of 8-18 experiments. Flux data from each condition 
was fit with a double-exponential equation to obtain the rate constants for KATP-dependent 
efflux, k2, where lines show mean fitted relationships. Graphical representation of the 
determined k2 rate constants are shown on the right of the corresponding cumulative efflux 
over time. *p< 0.05 as compared to WT (unpaired Student’s t test). 
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Figure 4.2- Homomeric Kir6.1-V65M (but not Kir6.1-V65L) expressed with SUR2A 
increases KATP channel activity under Metabolic Inhibition (MI) and in the presence of 
pinacidil in intact cells. Cumulative 86Rb+ efflux, as a function of time, was measured in GFP-
transfected control cells (black symbols), and in cells transiently expressing SUR2A with Kir6.1-
WT (white triangles), Kir6.1-V65M (blue squares) or Kir6.1-V65L (light grey circles). 
Experiments were done under basal conditions (A), in the presence of the K+ channel opener 
pinacidil (B), or metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (C). The data 
represents the means + S.E.M. of 3 experiments. Flux data from each condition was fit with a 
double-exponential equation to obtain the rate constants for KATP-dependent efflux, k2 (right), 
where lines show mean fitted relationships. Graphical representation of the determined k2 rate 
constants are shown on the right of the corresponding cumulative efflux over time. * p< 0.05 as 
compared to WT (unpaired Student’s t test). 
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Figure 4.3- Homomeric Kir6.2-V64M–but not Kir6.2-V64L– expressed with SUR1 
increases KATP channel activity in basal conditions and in the presence of Diazoxide in 
intact cells. The cumulative 86Rb+ efflux, as a function of time, was measured in GFP-
transfected control cells (black symbols), and in cells transiently expressing SUR1 with Kir6.2-
WT (white triangles), Kir6.2-V64M (navy squares) or Kir6.2-V64L (dark grey circles).
Experiments were done in basal conditions (A), in the presence of the K+ channel opener 
diazoxide (B), or metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (C). The data 
represents the means + S.E.M. of 3-5 experiments. Flux data from each condition was fit with a 
double-exponential equation to obtain the rate constants for KATP-dependent efflux, k2 (right), 
where lines show mean fitted relationships. Graphical representation of the determined k2 rate 
constants are shown on the right of the corresponding cumulative efflux over time. * p< 0.05 as 
compared to WT (unpaired Student’s t test). 
52 
  
  
Figure 4.4- Homomeric Kir6.2-V64M–but not Kir6.2-V64L–with SUR2A 
increases KATP channel activity in basal conditions and in the presence of pinacidil 
in intact cells. The cumulative 86Rb+ efflux, as a function of time, was measured in 
GFP-transfected control cells (black symbols), and in cells transiently expressing 
SUR2A with Kir6.2-WT (white triangles), Kir6.2-V64M (navy squares) or Kir6.2-
V64L (dark grey circles).  Experiments were done in basal conditions (A), in the 
presence of the K+ channel opener pinacidil (B), or metabolic inhibitors (MI) 
oligomycin and 2-deoxy-d-glucose (C). The data represents the means + S.E.M. of 3-6 
experiments. Flux data from each condition was fit with a double-exponential equation 
to obtain the rate constants for KATP-dependent efflux, k2 (right), where lines show 
mean fitted relationships. Graphical representation of the determined k2 rate constants 
are shown on the right of the corresponding cumulative efflux over time. * p< 0.05 as 
compared to WT (unpaired Student’s t test). 
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These trends were also seen in the presence of diazoxide or pinacidil (Figure 4.3B and 4.4B). In 
MI Kir6.2 WT, Kir6.2-V64M and Kir6.2-V64L reached the same maximum with comparable 
efflux rates, whether paired with SUR1 or SUR2, indicating that these mutations do not alter the 
expression of KATP channels (Figure 4.3C and 4.4C). Overall, compared to WT channels, the 
valine-to-methionine substitution in both Kir6.1 and Kir6.2 results in a gain of function in KATP 
activity, but the valine-to-leucine mutation exhibits comparable channel activity (Figures 4.1-
4.4).  
Kir6.2-V64M overactivity results from decreased ATP sensitivity 
The 86Rb+ efflux experiments demonstrate that the behavior of valine-to-methionine and valine-
to-leucine substitutions are consistent whether expressed in Kir6.1 or Kir6.2, but do not reveal 
underlying molecular mechanism(s). Unlike Kir6.2, Kir6.1-based channels quickly run down and 
require activatory nucleotides to maintain channel activity, making assessment of nucleotide 
sensitivity experimentally challenging (Babenko et al., 2000). To assess the details of increased 
channel activity, inside-out excised patch-clamp experiments on Kir6.2-WT-, Kir6.2-V64M- and 
V64L-based channels paired with SUR2A were carried out. Intrinsic sensitivity to ATP 
inhibition (in zero Mg2+) was similar for WT (Ki = 25 μM) and Kir6.2-V64L (Ki = 16 μM) 
channels.  However, KATP channels expressing Kir6.2-V64M exhibited a significant right shift in 
the [ATP]-response (Ki = 289 μM) (Fig. 4.5B). A decreased sensitivity to intracellular ATP 
could account for the increased activity of KATP channels under basal conditions in the intact cell 
(Figure 4.4A). PIP2 potentiation experiments were carried out on wild type and Kir6.2-V64M- 
based channels to assess ATP-independent open state stability (Enkvetchakul and Nichols, 2003) 
(Figure 4.6B). As seen in Figure 4.6C, wild type channels have a relative open probability of 
  
54 
  
  
Figure 4.5- Gain of function in Kir6.2-V64M due to decreased ATP-sensitivity.
Representative excised patch current recordings from COSm6 cells co-expressing SUR2A-
WT with Kir6.2-WT, Kir6.2-V64M or Kir6.2-V64L (A). Membrane potential was held at -
50mV, and currents were recorded continuously on-cell and in inside-out excised patches 
exposed to KINT in the absence or in the presence of 0.01, 0.1 or 1 mM ATP.  Dose-
response data (mean ± SEM 10 patches each) were fit to equation 1 to estimate the ATP 
concentration for half-maximal inhibition Ki: WT (24.7 µM), Kir6.2-V64M (16 µM), and 
Kir6.2-V64L (289.3 µM) (B).  
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Figure 4.6- Increased open state stability in Kir6.2-V64M-based channels underlies decreased 
ATP sensitivity. Representative KATP current traces for SUR2A-WT expressed with Kir6.2-WT (A)
or Kir6.2-V64M (B) following excision and in the presence of 10 mM ATP, 1mM ATP, or 5 µg/µL-
PIP2. The relative Po for individual patches from WT (white diamonds) and V64M (navy blue 
squares) was determined as a ratio of the maximum steady-state current upon excision, in the absence 
of nucleotides, over the maximum current measured in PIP2. The average Po (black bars) is the mean 
of 8 individual patches for each construct ± SEM. The relative Po for WT channels is 0.73 ± 0.08 
(WT) and 1.05 ± 0.07 for Kir6.2-V64Mbased channels.  *p< 0.05 as compared to WT (unpaired 
Student’s t test).  
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0.73±0.08 where as Kir6.2-V64M channels have a significantly increased Po of 1.05±0.07, 
indicating that the valine-to-methionine substitutions also affect channel PO.  
4.3 Discussion  
Cantu Syndrome, a complex multi-organ disease, was first described in 1982(Cantu et al., 
1982). Recently, several studies have demonstrated that the majority of CS patients have 
a mutation in ABCC9 (Harakalova et al., 2012; van Bon et al., 2012). In addition, two patients 
with clinically defined CS have been identified with coding mutations in KCNJ8 (Brownstein et 
al., 2013; Cooper et al., 2014), and two of these studies, together with the present study, confirm 
that the disease therefore results from gain of function in KATP channel activity that is generated 
by the SUR2 and Kir6.1 subunits encoded by these genes.  
Effects of equivalent residue mutations on KATP channel activity  
In a previously reported case of neonatal diabetes, a mutation at the equivalent position in Kir6.2 
(V64L) was reported along with an additional mutation at F60Y. When these mutations were 
expressed separately and channel activity was assessed, Kir6.2-V64L was determined to have no 
effect on KATP activity, and GOF in KATP activity was solely a result of the increased KATP 
channel activity from the F60Y mutation (Mannikko et al., 2009). Similarly, Kir6.2-V64A does 
not perturb KATP activity (Li et al., 2013). In the present study I have confirmed this finding, and 
shown that mutation of the equivalent valine to leucine in either Kir6.1 or Kir6.2 is without 
effect on recombinant channel activity. Conversely, mutation to methionine in either Kir6.1 or 
Kir6.2 generates a net gain of function. The inability of either leucine or alanine substitutions at 
this position to alter KATP activity might suggest that the bulkiness of the mutated residue at this 
position is relevant to if and how it alters KATP channel activity.   
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Mechanism of increased KATP channel activity through Kir6.1-V65M and Kir6.2-V64M-based 
channels  
Given the experimental difficulty of recording Kir6.1/SUR2 currents (Cooper et al., 2014), 
Kir6.2-V64M and V64L were instead paired with SUR2A to determine nucleotide sensitivity of 
KATP channels formed with each mutation. In excised patches, the ATP-sensitivity of Kir6.2-
V64M based channels, but not Kir6.2-V64L, was significantly reduced, compared to Kir6.2-WT 
channels.  This result is consistent with the overall gain of function in channel activity in Kir6.2-
V64M and Kir6.1-V65M being a result of decreased ATP-sensitivity (Figure 4.5). As has 
previously been described, mutations in Kir6.2 can reduce ATP sensitivity by two distinct 
mechanisms: 1) by directly altering ATP binding and/or 2) by increasing ATP-independent open 
probability, thus indirectly reducing ATP sensitivity (Koster et al., 2008a). By measuring the 
relative PIP2 activation of Kir6.2-V64M compared to Kir6.2-WT-based channels, we have 
shown that the Po is increased in the absence of ATP (Figure 4.6). This result is consistent with 
this mutation lying outside the ATP binding pocket, and thereby altering ATP sensitivity 
indirectly. 
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CHAPTER g: DIFFERENTIAL MECHANISMS OF CANTU SYNDROME-ASSOCIATED 
GAIN-OF-FUNCTION MUTATIONS IN THE ABCC9 (SUR2) SUBUNIT OF THE KATP 
CHANNEL 
5.1 Introduction 
The functional consequences of multiple uncharacterized CS-mutations remain unclear.  In this 
paper, we have focused on determining the functional consequences of 3 documented human CS-
associated ABCC9 mutations: human P432L, A478V and C1043Y. The mutations were 
engineered in the equivalent position in rat SUR2A (P429L, A475V and C1039Y) and each was 
co-expressed with mouse Kir6.2. Using macroscopic rubidium (86Rb+) efflux experiments, we 
show that KATP channels formed with P429L, A475V or C1039Y mutants enhance KATP activity 
compared to WT channels. We used inside-out patch-clamp electrophysiology to measure 
channel sensitivity to ATP-inhibition and MgADP-activation. For P429L and A475V mutants, 
sensitivity to ATP inhibition was comparable to WT channels, but activation by MgADP was 
significantly greater. C1039Y-dependent channels were significantly less sensitive to inhibition 
by ATP or by glibenclamide, but MgADP activation was comparable to WT. The results indicate 
that these three Cantu Syndrome mutations all lead to overactive KATP channels, but at least two 
mechanisms underlie the observed gain of function: decreased ATP inhibition and enhanced 
MgADP activation. 
5.2 Methods 
All rubidium efflux experiments were done by Monica Sala-Rabanal. Sequence alignment and 
homology model by Sun Joo Lee. 
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Homology Modeling 
Models of human SUR2A (Figure 5.1) were built using Modeller v9.8 from the template of the 
multidrug ABC transporter Sav1866 (2ONJ, to model the ‘open’ conformation) and 
heterodimeric ABC transporter TM287-TM288 (3QF4, to model the ‘closed’ conformation). The 
TM0 domain and L0 loop (1-281) were omitted due to lack of sequence homology to any 
proteins of known structure. Two extended loops unique to SUR2A were also omitted: one 
connecting TM1 and NBD1 (614-672) and a second connecting NBD1 and TM2 (920-966). A 
multiple sequence alignment (MSA) was carried out using ClustalW2 between SUR2 and the 
two template sequences. Due to low sequence identity, other proteins in the human ABCC family 
(ABCC1, 2, 3, 4, 5, 6, 8 and 10) were included in the alignment for TM1 and NBD1. Highly 
conserved sequence identity enabled a reliable sequence alignment of TMD2 and NBD2 by 
MSA between SUR2 and SUR1, 2ONJ, and 3QF4.  
5.3 Results 
Homomeric mutant channels are overactive in various metabolic conditions 
Cantu syndrome-associated mutations have been found throughout the coding sequence (Figure 
5.1). For the present study, we focused on two previously unexamined mutations (human P432L 
and C1043Y, corresponding to rat P429L and C1039Y, respectively), located in the TMD1 and 
TMD2 segments, and A478 (corresponding to rat A475V), also located in the TMD1 region.  To 
examine KATP channel activity in intact cells, we performed 
86Rb+ efflux experiments under four 
different conditions: basal; metabolic inhibition (MI); in the presence of pinacidil (PIN); and MI 
and pinacidil combined (MI + PIN). As shown in Figures 5.2 and 5.3, homomeric expression of  
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Figure 5.1- Cantu Syndrome mutations in SUR2 Alignment of SUR2 (ABCC9) with the 
multidrug ABC transporter Sav1866 (2ONJ) and heterodimeric ABC transporter TM287-TM288 
(3QF4), upon which we built homology models. Key structural domains TMD1,2 and NBD1,2) 
are indicated, as well as predicted alpha helical (pink) and beta strand (green) segments (A). 
Homology models of ‘open’ (B) and ‘closed’ (C) conformations of the SUR2A protein, which are 
based on Staphylococcus aureus Sav1866, a bacterial homolog of the human ABC transporter 
Mdr1 and hetero-dimeric ABC transporter TM287-TM288 (TM287/288) from Thermotoga 
maritime, respectively. Published CS mutations from previous reports are shown in green (open) 
and light pink (closed). 
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Figure 5.2- Increased channel activity in intact cells expressing homomeric P429L, A475V or 
C1039Y-containing KATP channels. 86Rb+ efflux, as a function of time, was measured in GFP-
transfected control cells (dashed), and in cells transiently expressing reconstituted Kir6.2-based KATP
channels with WT, P429L, A475V or C1039Y SUR2 subunits in homomeric configuration, in basal 
conditions (A), in the presence of metabolic inhibitors (MI) oligomycin and 2-deoxy-d-glucose (B), or in 
the K+ channel opener pinacidil (C), or in the presence of both MI and pinacidil (D). The data represent 
means + S.E.M. of 6-10 experiments. Flux data were fit with equation 1 (GFP) to obtain the rate 
constant k1 or equation 2 to obtain the rate constants for KATP-dependent efflux, k2 (Figure 5.3), where 
lines show mean fitted relationships. 
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Figure 5.3- KATP conductance is increased in basal and stimulated conditions in 
intact cells expressing homomeric P429L and A475V-based KATP channels. Rate 
constants for KATP-dependent 
86Rb+ efflux (k1 in gray, proportional to non-specific K
+
conductance and k2, proportional to KATP specific K
+ conductance), were calculated 
from data shown in Figure 5.2. *p< 0.05 as compared to WT (unpaired Student’s t test). 
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SUR2A-P429L, A475V or C1039Y channels, results in significantly higher basal 86Rb+ efflux 
rates compared to WT (Figure 5.2A and Figure 5.3A). P429L and A475V-based channels, but 
not those composed of C1039Y, also showed significantly higher rate of efflux compared to WT 
channels under MI conditions and in the presence of pinacidil (Figures 5.2B-C and 5.3B-C), 
consistent with the gain of function(GOF) observed in the basal condition. Maximal efflux rates 
(estimated using simultaneous exposure to MI and pinacidil) of P429L and A475V were 
comparable to SUR2A-WT, implying similar channel densities at the cell surface (Figure 5.2D 
and 5.3D). C1039Y showed significantly lower absolute fluxes in all stimulatory conditions 
(Figures 5.2B-D and 5.3B-D), implying a lower channel density at the membrane (Figure 5.4). 
 The ratio of KATP-dependent (k2) rate constants in basal, MI and pinacidil to the maximal 
KATP-dependent rate constant (k2 in MI+PIN) should reflect the relative activation of each 
channel in these specific conditions. In the basal condition, the ratio was higher for all three 
mutations, compared to WT, markedly so for C1039Y (Figure 5.4A). In pinacidil alone, while 
only P429L and A475V reach significance, the ratio of active channels in all three mutations are 
also increased (Figure 5.4C).  Together, the results suggest that each mutant will result in higher 
channel activity under any stimulatory conditions, particularly for C1039Y.  
C1039Y (hC1043Y) overactivity results from decreased ATP-sensitivity via increased Po 
86Rb+ flux assays provide evidence for overactivity in CS mutants, but do not provide any 
indication of underlying molecular mechanisms. We assessed the details of channel properties in 
inside-out excised patch-clamp electrophysiology experiments. Intrinsic sensitivity to ATP 
inhibition (in zero Mg2+), was similar for WT, P429L and A475V channels (Ki = 7-9 μM). 
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Figure 5.4- Relative KATP conductance is markedly increased in basal and stimulated 
conditions in intact cells expressing homomeric C1039Y KATP channels. The ratio of 
the rate constants for KATP-dependent 
86Rb+ efflux (k2) in basal and pinacidil- or MI-
stimulated conditions to the maximal activation (in MI+Pinacidil) is plotted for WT and 
mutant channels. *p< 0.05 as compared to WT (unpaired Student’s t test).  
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However, KATP channels expressing C1039Y exhibited a significant right shift in ATP-sensitivity  
 (Ki = 21.3 µM)(Figure 5.5B). A diminished sensitivity to intracellular ATP may account, at 
least in part, for the increased activity of C1039Y-based KATP channels in basal conditions in the 
intact cell (Figures. 5.2A and 5.3A). Consistent with reduced channel density, the maximal 
current in zero ATP was significantly lower in C1039Y channels than WT or the P429L and 
A475V mutant channels (Figure 5.5C).  
In PIP2 activation experiments, WT and C1039Y channels lost ATP sensitivity the more the 
patch was exposed to PIP2. Simultaneously, the maximum currents for WT channels increased 
while the maximum current in C1039Y channels activity remained the same (Figure 5.6). The 
ratio of the maximum current in zero ATP over max current in PIP2 for WT patches (0.70 ± 0.11) 
was significantly lower than that of C1039Y channel patches (1.26 ± 0.21), which implies 
increased intrinsic activity from C1039Y channels. 
Overactivity in P429L (hP432L) and A475V (hA478V) results from increased MgADP activation 
We investigated the current response to intracellular MgADP in the presence of 0.1 mM ATP 
(Figure 5.7A). MgADP-dependent activation was estimated as the ratio between the steady-state 
activated current in MgADP+ATP and the maximal current in zero ATP, immediately after 
excision (Figure 5.7B). In P429L, the relative current in MgADP was markedly higher than WT 
for P429L and A475V channels. Using this analysis, the current was also statistically higher for 
C1039Y channels. However, this analysis fails to account for the intrinsically lower sensitivity of 
C1039Y channels to ATP inhibition. An alternative estimation for the stimulatory action of Mg-  
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Figure 5.5- ATP-sensitivity is decreased in C1039Y channels. Representative excised patch 
clamp recordings from COSm6 cells co-expressing Kir6.2 and WT or CS mutant SUR2 subunits 
P429L, A475V or C1039Y (A). Membrane potential was held at -50mV, and negative currents 
(plotted as upward deflections) were recorded continuously on-cell and in inside-out excised 
patches exposed to KINT in the absence or in the presence of 0.01, 0.1 or 1 mM ATP; arrowheads
mark the point of excision. Dose-response data (mean ± SEM from 8-11 patches) was fit with 
equation 3 to estimate the ATP concentration for half-maximal inhibition Ki: WT (9 µM), P429L 
(9 µM), A475V (7 µM), and C1039Y (21 µM) (B). The maximum patch current determined 
immediately following patch excision (mean ± SEM from 8-11 patches) (C). 
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Figure 5.6- C1039Y channels decreased ATP-sensitivity is due to increased Po
Representative KATP current traces following excision and in the presence of 1 mM ATP or 5 
µg/µL-PIP2 as indicated(A). Relative Po determined as a ratio of the maximum steady-state 
current in the patch upon excision, in the absence of nucleotides, over the maximum current 
measured in PIP2. Individual patch data represented by symbols (n = 7-10); bars are the 
means ± SEM respectively, where the relative Po for WT= 0.70 ± 0.11 and 1.26 ± 0.21 for 
C1039Y (B).. *p< 0.05 as compared to WT (unpaired Student’s t test).  
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Figure 5.7- P429L and A475V show enhanced MgADP activation  Representative KATP current 
traces following excision and in the presence of nucleotides as indicated (A). Relative MgADP 
activation in individual patch data represented by symbols (n = 11-24); bars are the means ± SEM 
respectively (B). *p< 0.05 as compared to WT (unpaired Student’s t test). Insert shows the mean 
current measured in patches in the presence of 0.1 mM Mg-free ATP (from Figure 5.5B) subtracted 
from the mean value of steady-state current measured in patches in the presence of MgADP (from 
Figure 5.7A). Error bars represent the propagated error from both experiments half-time of activation 
by MgADP (C). 
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nucleotides is the ratio of current in MgADP+ATP to the current in Mg-free ATP alone (Figure 
5.7B, inset). This analysis implies no difference in the MgADP activation of C1039Y and WT 
channels. In addition, while the MgADP activation for P429L and A475V channels is more rapid 
than WT, activation of C1039Y channel is even slower than WT (Figure 5.7C). 
Gain of function is reduced in heteromeric mutant channels 
All documented CS patients with mutations in ABCC9 are heterozygous. To mimic the predicted 
heteromeric composition of channels in such patients we also expressed each mutation in a 1:1 
ratio with SUR2A-WT plus Kir6.2-WT, and assessed channel activity by 86Rb+ efflux 
experiments (Figures 5.8 and 5.9). In all conditions P429L, A475V and C1039Y heteromeric 
channels display no significant increases in the rates of 86Rb+ efflux, compared to WT channels 
(Figures 5.8A and 5.9A). However, when normalized to the maximal efflux rates, channels with 
heteromeric expression of C1039Y are still considerably more active than WT. Additionally, in 
the heteromeric state, maximal C1039Y channel fluxes were markedly higher than in the 
homomeric state (Figure 5.9D). Taken together, these results imply a partial rescue of the 
surface expression of C1039Y subunits by WT subunits (Figure 5.7B-D and 5.8B-D). 
Altered response to glibenclamide in C1039Y channels 
Some NDM patients with GOF mutations in Kir6.2 or SUR1 have successfully switched from 
insulin therapy to KATP channel inhibitors, such as glibenclamide (Zung et al., 2004). However, a 
correlation between increased channel activity and the diminished effectiveness of such drugs 
has been noted (Koster et al., 2005b). Therefore to test the effectiveness of glibenclamide on 
overactive P429L, A475V or C1039Y channels, expressed both homomerically and 
heteromerically, 86Rb+ efflux experiments were carried out in the presence of MI+ 10 µM  
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Figure 5.8- Channel activity in cells expressing heteromeric P429L, A475V or C1039Y-
based KATP channels. 86Rb+ efflux, as a function of time, was measured in GFP-transfected 
control cells (dashed), and in cells transiently expressing reconstituted Kir6.2-based KATP
channels with WT or 1:1 mixtures of WT and P429L, A475V or C1039Y mutant SUR2 
subunits, in basal conditions (A), in the presence of metabolic inhibitors (MI) oligomycin and 
2-deoxy-d-glucose (B), or in the K+ channel opener pinacidil (C), or in the presence of both 
MI and pinacidil (D). The data represent means + S.E.M. of 6-10 experiments. Flux data 
were fit with equation 1 (GFP) to obtain the rate constant k1 or equation 2 to obtain the rate 
constants for KATP-dependent efflux, k2 (Figure 5.9), where lines show mean fitted 
relationships. 
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Figure 5.9- KATP conductance normalized in the basal condition and in stimulated 
conditions for heteromeric P429L, A475V or C1039Y-based KATP channels. The rate 
constants for non-specific efflux (k1 represented by gray area) and KATP-dependent 
86Rb+
efflux (k2), proportional to KATP specific K
+ conductance, were estimated from data shown 
in Figure 5.8. *p< 0.05 as compared to WT (unpaired Student’s t test). 
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glibenclamide (Fig. 5.10). The time course of 86Rb+ effluxes shows an unusual behavior in that 
although initial fluxes are markedly lower than in MI without glibenclamide, the inhibition is not 
maintained through the time course of the assay. It is well understood that the inhibitory action 
of glibenclamide is a complex function of the metabolic conditions, and decreases under 
conditions of metabolic inhibition (Findlay, 1993; Koster et al., 1999). To account for this 
behavior, the efflux data in glibenclamide were again fit by equation 2, where negative values for 
k-2 result in the rate of efflux actually increasing with time for A475V and P429L channels. From 
this analysis, the ratio of the k2 in MI+glibenclamide and k2 in MI alone approximates the 
relative glibenclamide sensitivity (Figure 5.10C). While the sensitivity of A475V and P429L 
channels was not different from WT, C1039Y channels are notably less sensitive. Qualitatively 
similar results were obtained with channels expressed in heteromeric mixture with WT subunits 
(Figures 5.9B,D). As discussed below, this is consistent with similar findings for SUR1 
mutations that results in increased activity of the resultant KATP channels. 
5.3 Discussion 
Distinct mechanisms of KATP GOF in Cantu Syndrome ABCC9 mutations 
Cantu Syndrome (CS) is a rare disease characterized by complex vascular and skeletal 
anomalies, the underlying cellular and molecular mechanisms of which we are only now 
beginning to understand (Nichols et al., 2013). The majority of genotyped CS patients are 
heterozygous for mutations in the genes encoding ABCC9 (SUR2) (Harakalova et al., 2012; van 
Bon et al., 2012) in most cases, and KCNJ8 (Kir6.1) (Brownstein et al., 2013; Cooper et al., 
2014) in others. A select few of these mutations, to date, have been shown to form overactive 
KATP channels (Cooper et al., 2014; Harakalova et al., 2012), but most remain unexplored. Here, 
we characterized three CS-associated ABCC9 mutations, namely P429L (hP432L), A475V  
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Figure 5.10- Decreased sensitivity to glibenclamide inhibition in C1039Y channels. 86Rb+ efflux, as a 
function of time, was measured in GFP-transfected control cells, and in cells transiently expressing KATP
channels composed of Kir6.2 plus WT or mutant SUR2 subunits (A), as well as in cells expressing 1:1 
mixture of WT and mutant SUR2 subunits (B). Experiments were performed in MI+ glibenclamide. The 
data represent the means + S.E.M. of 3-6 experiments. Data were fit with equation 2 to obtain rate constants 
for KATP-dependent efflux (k2). k2.in glibenclamide + MI was divided by k2 in MI for each condition(C,D).  
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 (hA478V) and C1039Y (hC1043Y), that localize to distinct regions of the SUR2 protein 
(Figure 5.1). Each mutation leads to KATP channel gain of function (GOF) (Figures 5.2-5.7), 
consistent with previous findings on isolated CS-associated ABCC9 mutations (Harakalova et al., 
2012).  
In the only previous assessment of CS-associated ABCC9 mutations, Harakalova et al. 
measured channel sensitivity to ATP in the presence of Mg2+. Mg-nucleotides have complex 
activatory/inhibitory effects on KATP channels: MgATP can both inhibit the Kir6.X subunit and 
be hydrolyzed to activatory MgADP at the SUR subunits (Nichols, 2006). Therefore, such an 
analysis cannot separate mutant effects on ATP inhibition from those on Mg-nucleotide 
activation. By separately assessing channel activity in response to Mg-free ATP and to MgADP 
we show that CS-associated ABCC9 mutations lead to increased channel activity via different 
mechanisms, as has also been observed with NDM-associated ABCC8 mutations (de Wet et al., 
2008; de Wet et al., 2007; Masia et al., 2007; Zhou et al., 2010). Specifically, we demonstrate 
two mechanisms of increased channel activity, where P429L and A475V channels results from 
increased MgADP activation and C1039Y channels results predominantly from decreased ATP 
sensitivity. 
KATP mutations in SUR1 have been shown to decrease ATP-sensitivity (Takagi et al., 
2013; Tarasov et al., 2008). There are at least two mechanisms to decrease ATP sensitivity in 
KATP channels including decreased ATP binding or increased open probability (Po) (Denton and 
Jacobson, 2012). Considering the SUR2-C1039Y mutation is not likely to disrupt binding of 
ATP to the Kir6.X subunit we tested for changes in channel Po. The simple gating model, 
Ci↔C↔O, Ci represents closed channels inhibited by ATP, C represents intrinsic closing and O 
represents open channels. PIP2 activates KATP currents by increasing the intrinsic Po, or in 
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reference to a simple gating model, PIP2 forces channels to stay in the open state, preventing 
transition from C to Ci by ATP binding (Shyng and Nichols, 1998). Therefore, the ability of PIP2 
to decrease ATP sensitivity, but not increase the maximum currents from C1039Y channels 
imply the Po of these channels is near 1 (relative Po = 1.26 ± 0.21) which is significantly higher 
than the Po for WT channels (relative Po = 0.70 ± 0.11) (Figure 5.6), and thus ultimately results 
in decreased ATP sensitivity (Figure 5.5).  
In addition to increasing channel activity, homomeric expression of C1039Y appears to 
decrease expression of channels in the membrane. A similar dual effect of GOF mutations in 
both Kir6.2 (Lin et al., 2013) and SUR1 (Zhou et al., 2010) has previously been shown. In these 
previous examples, decreased surface expression was demonstrated by western blot analysis. 
Significant rescue of channel activity in heteromeric C1039Y/WT channels is consistent with the 
patterns from such  mutations (Figures 5.8 and 5.9), suggesting that in addition to reducing 
ATP-sensitivity of expressed channels, C1039Y also decreases KATP surface expression. 
Implications for tissue pathology in in Cantu Syndrome 
Kir6.1 GOF mutations have also been found in two Cantu Syndrome patients (Brownstein et al., 
2013; Cooper et al., 2014), confirming Kir6.1/SUR2 as the key subunit combination generating 
the overactive channels. Given the experimental difficulty of recording Kir6.1/SUR2 currents 
(Cooper et al., 2014), we used Kir6.2+SUR2A channels in the present study. ABCC9 encodes 
two splice variants: SUR2A and SUR2B, which vary only in the last 40 amino acids. All CS-
associated SUR2 mutations identified to date are located within the core of the SUR2 protein, 
such that these mutations will be present in both SUR2A and SUR2B. SUR2A is predominant in 
skeletal muscle and heart, while SUR2B is expressed in the vasculature. Kir6.1/SUR2B may be 
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the more dramatically affected combination, since vascular phenotypes seem to predominate in 
CS patients (Nichols et al., 2013). Conversely, neither skeletal muscle weakness nor shortening 
of the QT interval on the ECG have been noted, as might be expected if Kir6.2/SUR2A were 
markedly activated.  
 The severity of disease varies between Cantu Syndrome patients such that not all reported 
features are exhibited by all patients. Direct comparison of the phenotypes of patients carrying 
the A475V and C1039Y equivalent mutations (Harakalova et al., 2012) revealed hypertrichosis, 
macrosomia, macrocephaly, coarse features, cardiac anomalies, and umbilical hernia to be 
common to both. However, pulmonary hypertension, cardiomegaly, osteopenia, 
hyperextensibility and lymphedema were only reported for the A475V equivalent patient. The 
reduced sensitivity to ATP inhibition, due to the C1039Y mutation, results in greater relative 
basal channel activity than the enhanced Mg-nucleotide activation, due to A475V. However, a 
less severe disease phenotype for C1039Y suggests that reduced expression of this mutation may 
also be a consequence in vivo, as has also been reported for SUR1 NDM mutations (Zhou et al., 
2010). 
Implications for therapeutic intervention in Cantu Syndrome 
Finally, sulfonylureas, which inhibit KATP channels via interaction with the SUR subunits, are 
effective treatments for NDM patients with ABCC8-activating mutations (Babenko et al., 2006), 
and are promising potential therapies for Cantu Syndrome (Nichols, 2013 #7510). However, 
GOF mutations in Kir6.2 (Koster et al., 2005a) and SUR1 (Takagi et al., 2013) frequently also 
decrease sensitivity to sulfonylureas, which may result in a lack of sulfonylurea therapeutic 
efficacy in patients with these mutations. Assessment of 86Rb+ efflux in glibenclamide 
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demonstrates that WT, P429L and A475V channels show complex time dependence of efflux 
(Figure 5.10). Each required a very negative k-2 rate constant, which is indicative of channel 
activation versus inactivation. We interpret this activation to be reflective of a loss of 
glibenclamide inhibition over time. Divergent from the others, the k-2 for C1039Y has a very 
small positive value, which is consistent with some channel inactivation. Similarly, k2 values in 
MI+glibenclamide WT, P429L and A475V channel activity drops to less than 10% in MI alone 
while C1039Y activity drops to ~50%. Taken together this would indicate that the C1039Y 
channel is glibenclamide insensitive. However, in general, SUR2 sensitivity to sulfonylureas is 
much lower than SUR1-sensitivity (Dorschner et al., 1999). Therefore, given the further 
reduction in drug sensitivity of GOF mutants, the introduction of sulfonylureas to treat CS 
patients is likely to require high doses, which would result in undesired inhibition of SUR1-
based KATP channels. SUR1 inhibition can lead to hypoglycemic effects, which will need to be 
carefully considered. Such concerns may ultimately make necessary the development of Kir6.1 
or SUR2 specific inhibitors to provide a safer and more effective treatment options for CS 
patients. 
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CHAPTER j: DISCUSSION 
GOF in KATP channel underlies CS 
In 2012, genetic analysis of 2 cohorts of CS patients demonstrated that the majority have 
mutations in ABBC9, which encodes the SUR2 protein (Harakalova et al., 2012; van Bon et al., 
2012). Initial studies of a few CS-SUR2 mutations expressed with Kir6.2 demonstrated increased 
KATP channel activity (Harakalova et al., 2012). My analysis of new, previously uncharacterized 
CS-associated SUR2 mutations confirms this effect. In 2013, two additional CS patients were 
reported (Brownstein et al., 2013; Cooper et al., 2014) who presented with the hallmark features 
of CS, but were negative for a SUR2 mutation. Instead, both carry a mutation in KCNJ8 (Kir6.1-
V65M and C176S). I also demonstrate that each of these CS-Kir6.1 mutations (V64M and 
C176S) also increase KATP channel activity. Therefore, having demonstrated that both SUR2 and 
Kir6.1 CS-mutations increase KATP channel activity, I conclude that gain of function (GOF) in 
KATP channel activity underlies CS. The previous data showing that multiple SUR2 mutations 
result in a GOF in channel activity was strong evidence to support increased KATP channel 
activity underlying CS. However, the demonstration that CS- associated mutations in Kir6.1 also 
increase KATP channel activity was crucial in confirming this, as there are reports of SUR2 
involvement in KATP channel independent activity (Aggarwal et al., 2010; Stoller et al., 2010). 
Molecular basis of KATP channel gain of function 
Gain of Function (GOF) in channel activity can arise from increases in channel activity and/or 
from increased channel expression. The majority of Neonatal Diabetes Mellitus (NDM) patients 
carry mutations in Kir6.2 or SUR1 that increase KATP channel activity (Babenko et al., 2006; 
Gloyn et al., 2004). Several mechanisms by which NDM mutations enhance KATP channel 
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activity have been described (Denton and Jacobson, 2012). For example, Kir6.2 NDM mutations 
have been shown to enhance channel open probability (Po) (Mannikko et al., 2009) or to decrease 
ATP binding (Proks et al., 2004). SUR1 NDM mutations have been shown to enhance KATP 
channel activity by enhancing ATPase activity (de Wet et al., 2008), by allosteric changes that 
indirectly decrease ATP sensitivity (Babenko et al., 2006), or by increased MgADP activation 
(Masia et al., 2007). However, no molecular details of CS-causing Kir6.1 or SUR2 mutation 
mechanisms have previously been described. 
 In this project, I have sought to address this question. To do this, I examined nucleotide 
sensitivity for SUR2 mutations in inside out patch clamp experiments. For Kir6.1 mutations, 
nucleotide sensitivity was also assessed and, by estimating PIP2 activation, I also determined 
relative Po. CS-associated Kir6.1 and SUR2 GOF mutations result from several distinct 
mechanisms. I have, for example, demonstrated that SUR2 mutations can disrupt response to 
ATP or MgADP. The SUR2-C1039Y mutation results in GOF, by indirectly decreasing 
sensitivity to ATP inhibition without affecting MgADP activation. Conversely, both SUR-P429L 
and A475V increase channel activity by enhancing MgADP activation. A third mechanism, in 
both Kir6.1 mutations (Kir6.1-V65M and C176S), enhances Po, thereby indirectly decreasing 
channel sensitivity to ATP inhibition. Additionally, because one of the SUR2 mutations 
(C1039Y) unexpectedly demonstrates decreased trafficking, surface expression may also 
confound disease presentation. 
Kir6.1/SUR2 expression and CS symptoms 
At the tissue level, the effects of NDM and CS mutations depend on the tissues where the 
channels are expressed, and on how sensitive each tissue is to KATP channel activity. Kir6.1 is 
expressed ubiquitously and has been confirmed in the vasculature (Inagaki et al., 1995c). SUR2 
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can be alternatively spliced into two major isoforms: SUR2A and SUR2B (Isomoto et al., 1996). 
The splice variant SUR2A is expressed in the heart and skeletal muscle (Chutkow et al., 1996). 
In parallel to Kir6.1, the splice variant SUR2B is also expressed ubiquitously and confirmed in 
the vasculature (Chutkow et al., 1996; Inagaki et al., 1995c).Conversely, Kir6.2 and SUR1 are 
expressed primarily in pancreatic beta cells, brain, heart and skeletal muscle (Inagaki et al., 
1995a). 
There have been several reports of tissues expressing both Kir6.1 and Kir6.2 (Insuk et al., 
2003; Teramoto et al., 2009). However, to date, there appears to be no overlap in symptoms of 
CS and NDM patients experience. CS patients generally present with cardiomegaly, 
hypertrichosis, macrocephaly, osteochrondyslpasia, and macrosomia (Grange 2006, van Bon 
2012, and Harakalova 2012). Conversely, NDM patients experience hyperglycemia and 
hypoinsulinemia along with neurological complications in the most severe cases. This lack of 
overlap in symptoms implies that where expression of pore-forming subunits overlaps, the 
predominance of non-mutated pore-forming subunits might be protective.  
Potential for CS genotype/phenotype correlation 
NDM presents with varying severity, from Transient NDM (TNDM), to Permanent NDM 
(PNDM), to developmental delay, epilepsy and neonatal diabetes (DEND) (Naylor et al., 2011). 
The severity of the disease correlates with the molecular severity of the Kir6.2 or SUR2 
mutations (Flanagan et al., 2009; Hattersley and Ashcroft, 2005). TNDM patients have 
hyperglycemia and hypoinsulinemia that is present at birth, but is not permanent. The Kir6.2 or 
SUR1 mutations associated with this form of NDM have weak shifts in ATP sensitivity or 
enhancement of MgADP activation (Gloyn et al., 2005; Proks et al., 2004).  PNDM patients have 
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hyperglycemia and hypoinsulinemia that also appears within the first 6 months of life, but 
persists throughout life. Compared to TNDM mutations, the Kir6.2 and SUR1 mutations in this 
form of NDM typically have larger shifts in ATP sensitivity or enhancement of MgADP 
activation (Gloyn et al., 2004; Proks et al., 2004). Along with the diabetes, DEND patients can 
have developmental delay and epilepsy. Intermediate DEND (iDEND) is a form of DEND with 
milder developmental delay and no epilepsy. Kir6.2 and SUR1 mutations causing isDEND and 
DEND have the most severe shifts in ATP sensitivity or enhancement of MgADP activation 
compared with all other forms of this disease (Proks et al., 2004; Proks et al., 2006; Proks et al., 
2005). Is there a range of symptoms in CS? CS patients generally present with cardiomegaly, 
hypertrichosis, macrocephaly, osteochrondyslpasia, and macrosomia (Grange 2006, van Bon 
2012, and Harakalova 2012).There are also symptoms that are only found in small subsets of 
patients, including patent ductus arteriosus (PDA), pericardial effusions, and valvular 
abnormalities. This raises the question: do CS mutations correlate with symptomatic 
presentation? 
In considering this question with just the patients with Kir6.1 or SUR2 mutations which I 
have functionally described (Table 6.1), the major common symptoms were present in all. The 
mutations carried by patients who have all the major symptoms with the addition of at least one 
of the rare symptoms included: Kir6.1-V65M, C176S or SUR2-A475V.Based on 86Rb+ efflux 
experiments (Figures 3.1A and 3.2A, Figure 4.1, and Figures 5.2A and 5.3A) these mutations 
result in the largest fluxes in the basal and pinacidil stimulated conditions. Of the other SUR2 
mutations considered, A475V has one of the largest increases in relative 86Rb+ efflux under basal 
conditions. Both the CS-Kir6.1 patients carrying the Kir6.1-V65M and Kir6.1-C176S mutations 
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Table 6.1- Cantu Syndrome Mutations and Clinical Symptoms.  
 
Kir6.1-
V65M 
Kir6.1-
C176S 
SUR2-
P429L 
SUR2-
A75V 
SUR2-
A75V 
SUR2-
C1039Y 
Gender M M F F M F 
Inherited (Y/N) N N N Y unk N 
Alive (Y/N) Y Y Y Y Y Y 
Coarse face  + + + + + + 
congential 
hypertichosis  + + + + + + 
Macrosomia           
at birth  + + + + + + 
Macrocephaly unk + unk + + + 
developmental 
delay mild + - + - - 
cardiomegaly + + + - + - 
structural 
cardiac 
anaomalies + + - + + + 
pulmonary 
hypertension + - - + - - 
pericardial 
effusion - - - - - unk 
hypertrophic 
and/or dilated 
cardiomyopathy + + + - unk - 
lymphedema -   - - + - 
PDA unk + - unk unk unk 
 
  
The + symbols indicates clinical symptoms present in patients, - symbol indicates clinical 
symptoms that are absent in the patients. The unk designation indicates symptoms not test and/or 
reported in the patients.  Common CS symptoms are indicated in black and symptoms present only 
in small subsets of CS patients are indicated in red.  
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have similar symptoms and the mutant channels displayed comparable rates of 86Rb+ efflux in 
the basal condition (Figures 4.1 and 4.2). Taken together, potential genotype/phenotype 
correlations exist, but additional studies in a larger set of CS Kir6.1 and SUR2 mutations will 
need to be done to accompany the clinical findings reported.  
Potential for treating CS 
There is currently no specific treatment for CS. Sulfonylureas bind  directly to the SUR subunits 
of KATP channel to inhibit KATP channel activity (Ashfield et al., 1999).With the understanding 
that the molecular basis of CS is GOF in KATP channel activity, use of a sulfonylurea drugs,  such 
as glyburide, a KATP channel-specific inhibitor that is currently used to treat diabetes (Feldman, 
1985), may be a treatment option. However, a potential detrimental side effect to using 
glyburide, or other sulfonylurea drugs, as a CS treatment option, is that KATP channels containing  
SUR1 are typically ~100fold more sensitive to these drugs than KATP channels containing SUR2 
(Gribble et al., 1998). Even SUR2 mutations with reduced sulfonylurea sensitivity may be 
capable of being inhibited partially by these drugs, but perhaps require higher doses. However, in 
addition to the efficacy of these drugs to inhibit SUR2 based channels, they will also bind and 
inhibit SUR1-based channels from increasing insulin secretion, which can result in 
hypoglycemia. Thus, along with the potential benefits of administering sulfonylureas to CS 
patients, there would also be a risk of patients becoming hypoglycemic which, if left unmanaged, 
can be lethal. 
An alternate option to sulfonylureas would be inhibitors that target KATP channels 
composed of Kir6.1+SUR2A specifically. Currently, there is a reportedly Kir6.1-specific 
inhibitor, U-37883 or PNU-37883A. Electrophysiology experiments, in a heterologous 
expression system, demonstrate that PNU-37883A preferentially inhibits ~80% of Kir6.1 based 
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channels at 100µM, but also partially inhibits ~15% of Kir6.2-based channels (Surah-Narwal et 
al., 1999). While this Kir6.1 selective inhibitor is not be perfect, it may be a good starting point 
for the development of a specific CS treatment. 
Is there a Kir6.1/SUR2 loss of function (LOF) disease? 
Kir6.2 and SUR1 mutations which result in a loss of function (LOF) in KATP channel activity 
underlie Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) also known as congenital 
hyperinsulinemia (Darendeliler et al., 2002). PHHI is characterized by increased plasma levels of 
insulin in hypoglycemic conditions along with decreased levels of ketone bodies and free fatty 
acids (Aguilar-Bryan and Bryan, 1999), i.e., the opposite of NDM.  CS has now been identified 
as the result of Kir6.1/SUR2 GOF, but there is currently no known LOF disease caused by 
Kir6.1/SUR2 mutations. Sudden Infant Death Syndrome (SIDS), is characterized by the sudden 
and usually unexplained death of an infant (Dawes, 1968). Two Kir6.1 mutations (in-frame 
deletion E332del and a missense mutation V346I) identified in babies with SIDS results in LOF 
in KATP channel activity, when expressed with SUR2 (Tester et al., 2011). Though there are no 
reported SIDS patients to date with SUR2 mutations, multiple SIDS babies with a Kir6.1-LOF 
mutation make SIDS a strong candidate Kir6.1/SUR2 LOF disease.  
The tissues impacted by GOF in Kir6.1 and SUR2 most commonly include the heart, hair, 
vasculature and bone (Nichols et al., 2013). So what would be the result of LOF in those same 
tissues? Most CS patients have enlarged hearts (Grange et al., 2014) and, thus, in a disease linked 
with a LOF of KATP channel activity, a small heart might be anticipated.  The opposite of the 
failure of the ductus arteriosus to close, which is seen in CS, would be premature closure. When 
considering the hair of LOF patients, the converse of excessive hair growth, i.e., reduced or no 
hair would be potential symptoms. In the vasculature, CS patients have low blood pressure, and 
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the opposite of that, which may be present in LOF patients, would be hypertension. Finally, KATP 
channels have been reported in mesenchymal cells, which differentiate along an osteogenic 
lineage to form bone. Considering these various symptoms in different target tissues, CS may 
therefore, provide insights into Kir6.1/SUR2 LOF disease(s) 
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